Navigation überspringen
Kongressberichte & Archiv
ESMO World Congress on Gastrointestinal Cancer 2021
Session I:
Session II:
Session IV:
Session V:
Session VI:
Session VII:
Session VIII:
Session IX:
Session X:
International Conference on Malignant Lymphoma (ICML)
PLENARY SESSION
SESSION 1:
SESSION 2:
SESSION 3:
SESSION 4:
SESSION 5
SESSION 6:
SESSION 7:
SESSION 8:
SESSION 9:
SESSION 10:
SESSION 11:
SESSION 12:
SESSION 13:
EHA2021 Virtual Congress
Presidential Symposium
Late-Breaking Oral Session
Acute leukemia
ALL - CAR-T: Alternative targets and age groups
ALL - Novel subgroups and agents
Developments in AML therapy
Chronic myeloid malignancies
Response, resistance and treatment-free remission in CML
Population based studies in myeloid disorders
Novel targets in MDS
New pathways and molecular mechanisms in MPN
Novel therapies and targets in MPN
Chronic lymphoid malignancies
Clinical trials with targeted therapies in CLL
New treatment strategies for newly diagnosed multiple myeloma
New diagnostic and therapeutic approaches in multiple myeloma and AL amyloidosis
T cell re-directing therapies in relapsed/refractory multiple myeloma
Lymphoma
Hodgkin lymphoma - Clinical
Indolent & mantle cell lymphoma - Clinical
Aggressive lymphoma - CAR-T & transplant
Aggressive lymphoma - Combination therapies
Immunology
Cellular immunotherapy and gene therapy - Clinical
Fungal, bacterial and viral infections in hematology
Red & white cell disorders
New directions in aplastic anemia and PNH
Stem cell transplantation - GvHD
Stem cell transplantation - Clinical
Changing the scene on sickle cell disease
Changing the scene on thalassemias
2021 ASCO Annual Meeting
Plenary Session (LBA's) & Presscast Presentations
Breast Cancer
Interviews
Früher Brustkrebs neoadjuvant: Talazoparib bei triple-negativer BRCA 1/2 Keimbahnmutation
#ASCO21: WSG-ADAPT HR+/HER2- Ergebnisse in der Hochrisikogruppe
#ASCO21: Neoadjuvante De-Eskalation in WSG-ADAPT HR-/HER2+
#ASCO21: Olaparib nach (neo)adjuvanter Chemotherapie bei Keimbahnmutation BRCA 1/2
#ASCO21: Bedeutung der CSF ctDNA beim triple-negativen Brustkrebs (neoadjuvant)
#ASCO21: GeparNUEVO - neoadjuvant Durvalumab beim triple-negativen Brustkrebs
#ASCO21: Highlights zum metastasierten Brustkrebs
#ASCO21: Patientenumfrage zur Dosisanpassung beim metastasierten Brustkrebs
#ASCO21: Brustkrebs Highlights local/regional/adjuvant
#ASCO21: Metastasierter hormonpositiver Brustkrebs - Update zu den CDK4/6 Inhibitoren
Breast Cancer—Local/Regional/Adjuvant
Breast Cancer—Local/Regional/Adjuvant
Breast Cancer—Metastatic
Breast Cancer—Metastatic
CNS Cancer
Central Nervous System Tumors
Central Nervous System Tumors
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Gastrointestinal Cancer
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Gastrointestinal Cancer—Colorectal and Anal
Gastrointestinal Cancer—Colorectal and Anal
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Gynaecological Cancer
Gynecologic Cancer
Gynecologic Cancer
Haematological Malignancies
Hematologic Malignancies—Plasma Cell Dyscrasia
Hematologic Malignancies—Plasma Cell Dyscrasia
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Head & Neck Cancer
Head and Neck Cancer
Head and Neck Cancer
Lung Cancer
Lung Cancer—Non-Small Cell Metastatic
Lung Cancer—Non-Small Cell Metastatic
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Melanoma/Merkel cell carcinoma
Sarcoma
Sarcoma
Sarcoma
Urogenital Cancer
Genitourinary Cancer—Kidney and Bladder
Genitourinary Cancer—Kidney and Bladder
Genitourinary Cancer—Prostate, Testicular, and Penile
Genitourinary Cancer—Prostate, Testicular, and Penile
American Association for Cancer Research (AACR) Annual Meeting 2021
Important Papers presented at the Press Conference
Important Papers presented in Press Releases
ELCC 2021
47th Annual Meeting of the European Society for Blood and Marrow Transplantation
Choice of oral Sessions
CART-T Cells 1
CART-T Cells 2
Multiple Myeloma
Choice Educational Sessions
CAR-T Toxicity and Management
CARs in Childhood Malignancy
New developments in the field of CAR cell therapy
Satellite Symposia
Present and future approaches with CAR T cell therapy in B-cell malignancies
Targeting the immune system in multiple myeloma: CAR T cell therapy and beyond
Brustkrebsinfotag 2021
News der Leitlinienkommission der AGO Mamma 2021
Archiv 2020
2020 San Antonio Breast Cancer Virtual Symposium
Press Briefing
Interviews geführt von Renate Haidinger, Brustkrebs Deutschland e.V.
Interview mit Ingo Bauerfeind, Landshut
Interview mit Nadia Harbeck, München
Interview mit Christian Jackisch, Offenburg
Interview mit Wolfgang Janni, Ulm
Interview mit Wolfgang Janni, Ulm
Interview mit Michael Patrick Lux, Würzburg
Interview mit Volkmar Müller, Hamburg
Interview mit Volkmar Müller, Hamburg
Interview mit Christoph Thomssen, Halle (Saale)
Interview mit Michael Untch, Berlin-Buch
Interview mit Michael Untch, Berlin-Buch
Interview mit Achim Wöckel, Würzburg
Interview mit Achim Wöckel, Würzburg
General Sessions
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
All-Virtual 62nd ASH Annual Meeting and Exposition
Press Briefings
Press Briefing on Disparities in Health Care: Diversity, Equity, and Inclusion (DEI)
Press Briefing on What’s on the Horizon: Practice-Changing Clinical Trials
Press Briefing on Hematologic Aspects of the Pandemic: Advancing the Study of COVID-19
Press Briefing on Advancing New Frontiers: Genome Editing & Cellular Therapy
Press Briefing on Selected Late-Breaking Abstracts
Plenary Scientific Session
Late-Breaking Abstracts Session
Choice of two Scientific Workshops on Lymphoid Malignancies
Scientific Workshop on Tumor Immune Interactions
Scientific Workshop on Tumor Immune Interactions
Satellite Symposia
Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management
Medical Crossfire®:Exploring the Modern Management of Acute Lymphoblastic Leukemia from AYA to Adult
A Fresh Look at CAR T-Cell Therapy: Recent Advances, New Evidence, and Evolving Paradigms to Improve Patient Care
Oral Sessions
Hemoglobinopathies
Coagulation & Platelet Disorders
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
Hodgkin Lymphoma and T/NK Cell Lymphoma
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
Chronic Myeloid Leukemia
Myeloproliferative Syndromes
Myelodysplastic Syndromes
CLL
Myeloma/Amyloidosis: Therapy excluding Transplantation:
52th Congress of the International Society of Paediatric Oncology (SIOP)
Sessions Highlights
Wednesday
Thursday
Friday
Saturday
Building Bridges to ensure best possible outcomes for children and adults with ALL
DGHO, OeGHO, SGMO und SGH+SSH Jahrestagung 2020 VIRTUAL
Best Abstracts
Innovative Hämatologie
EBCC-12 European Breast Cancer Conference
ESMO VIRTUAL 2020
Presidential Symposia
Presidential Symposium I
Presidential Symposium II
Presidential Symposium III
Breast cancer
Interviews
Proffered Paper - Breast cancer, early stage
Proffered Paper - Breast cancer, metastatic 1
Proffered Paper - Breast cancer, metastatic 2
Thoracic Cancer
Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies
Proffered Paper - NSCLC metastatic 1
Proffered Paper - NSCLC metastatic 2
CNS- & Skin Tumours, NETs & Sarcoma
Proffered Paper - NETs
Proffered Paper - Sarcoma
Proffered Paper - CNS tumours
Proffered Paper - Melanoma and other skin tumours
GU Tumours
Proffered Paper - GU, non prostate 1
Proffered Paper - GU, non prostate 2
Proffered Paper - GU, prostate
Gynaecological Cancers
Proffered Paper 1 - Gynaecological cancers
Proffered Paper 2 - Gynaecological cancers
Head & Neck & GI Cancers
Proffered Paper - Head & Neck cancer
Proffered Paper - GI, colorectal
Proffered Paper - GI, non colorectal
Immunotherapy, Translational Research & Basic Science
Proffered Papers - Investigational immunotherapy
Proffered Papers - Developmental therapeutics
Proffered Papers - Basic Science
Proffered Papers - Translational research
SARS-CoV-2 & Cancer
Proffered Paper - SARS-CoV-2 and cancer 1
Proffered Paper - SARS-CoV-2 and cancer 2
Supportive & Palliative Therapy, Public Policy
Proffered Paper - Supportive and palliative care
Proffered Paper - Public Policy
ESMO VIRTUAL CONGRESS 2020
VIRTUAL EBMT 46th Annual Meeting 2020
CAR-based Cellular Therapy
ACUTE LYMPHOBLASTIC LEUKEMIA
LARGE B-CELL LYMPHOMA
NON-HODGKIN LYMPHOMA
MULTIPLE MYELOMA
SIDE EFFECTS
MISCELLANEOUS
IASLC 21st World Conference on Lung Cancer
The 22nd ESMO World Congress on Gastrointestinal Cancer - Virtual Congress
Session I: Cancer of the Pancreas and Biliary Tract
Session II: Hepatocellular Cancer
Session III: Esophageal and Gastric Cancer
Session IV: Gastrointestinal Stromal Tumors (GIST); Neuroendocrine Tumors (NET)
Session V: Molecular Screening; Imaging; Artificial Intelligence
Session VI: Colorectal Cancer I
Session VII: Colorectal Cancer II
Session IX: Rectal Cancer
Virtual Edition of the 25th Annual Congress of the European Hematology Association
Presidential Symposium
Plenary Session I
Plenary Session II
Late-Breaking Oral Session - available fromSaturday June 13 8.30 AM
Oral Sessions
Acute Leukemia
Lymphoma
Chronic Myeloid Neoplasms
Chronic Lymphoid Neoplasms
Immunology
Red & White Cell Disorders
ITP:
Link to Satellite Session - Live Fri 12 Jun 17:30-18:30
e-Poster Presentations
ASCO20 Virtual Scientific Meeting
Studies presented at press briefings
Pre-Meeting Presentation
Press Briefing May 28
Plenary Session Abstracts
Oral Sessions
Breast Cancer I
Breast Cancer II
Brustkrebs Interviews
Gynecologic Cancer
Gynäkologische Karzinomata - Interviews
SAMO Virtual Workshop on COVID19:
Coronavirus/Brustkrebs
AGO MAMMAKARZINOM - State of the Art Meeting 2020
Keynote-Lecture: Fatima Cardoso
Vormittag 1
Vormittag 2
Nachmittag 1
Nachmittag 2
Interviews im Rahmen einer Kooperation von Oncoletter mit Brustkrebs Deutschland e.v.
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Andreas Schneeweiss, Heidelberg, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Volkmar Müller, Hamburg und Wolfgang Janni, Ulm, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Diana Lüftner Berlin, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Christian Jackisch, Offenbach & Andreas Schneeweiss, Heidelberg, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Bernd Gerber, Rostock zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Volkmar Müller und Ute-Susann Albert, Frankfurt, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Achim Rody, Lübeck, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Achim Wöckel, Würzburg und Christoph Thomssen, Halle zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Michael Lux, Erlangen, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit David Krug, Kiel, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Christoph Thomssen, Halle, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Nina Ditsch, München, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Marc Thill, Frankfurt und Michael Untch, Berlin, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Tanja Fehm, Düsseldorf und Elmar Stickeler, Aachen, zum Thema:
Gespräch mit Kerstin Rhiem, Köln, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Jens Huober, Ulm, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Thorsten Kühn, Esslingen und Jens Uwe Blohmer, Berlin, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Hans H. Kreipe, Hannover, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Ingo Bauerfeind, Landshut und Nina Ditsch, München, zum Thema:
Ten Years of ETOP
2nd Zurich Brain Metastasis Symposium
Experimental Studies
Keynote Lectures
Updates on Therapeutic Approaches
Brain Metastasis: Disease Updates
Controversies & Hot Topics in the Diagnosis and Management of CNS Metastasis
SABCS - 42nd Annual San Antonio Breast Cancer Symposium
Press Conferences
Wednesday, Dec. 11
Thursday, Dec. 12
Friday, Dec. 13
General Sessions 1-6
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
GENERAL SESSION 5:
GENERAL SESSION 6:
Interviews - Breast Cancer
HER 2-positiver, metastasierter Brustkrebs: HER2CLIMB Studie mit Tucatinib
HER 2-positiver, metastasierter Brustkrebs: DESTINY-Breast01 Studie mit Trastuzumab Deruxtecan
HER 2-positiver Brustkrebs adjuvant: APHINITY Studie, 2. Zwischenanalyse
HER 2-positiver Brustkrebs adjuvant: ATEMPT Studie T-DM1 gegen Paclitaxel plus Trastuzumab
Einsatz von Capecitabine Neo/Adjuvant
GEPARX Studie: Denosumab im Vergleich zu zwei Nab-Paclitaxel Schemata - neoadjuvant
Immuncheckpoint-Inhibitoren: Durvalumab beim metastasierten BC und Pembrolizumab neoadjuvant und adjuvant bei TNBC
pCR bei neoadjuvanter Therapie mit Atezolizumab beim TNBC?
Neues zu CDK4/6 Inhibitoren (HR+ & HER2-)
Wenn der Brust-Tumor weg ist nach neoadjuvanter Therapie: Muss noch operiert werden?
Teil- oder Ganzbrustbestrahlung nach Brust erhaltender Therapie. Was für wen?
Schweizer Expertenrunde mit einigen Highlights vom SABCS:
Round Table mit Brustkrebs Deutschland e.V.
61st ASH Annual Meeting and Exposition
Highlights of the Conference: Statements & Opinions
ALL
Multiples Myelom
Multiples Myelom
Lymphome
Press Briefings
Saturday, December 7:
Saturday, December 7:
Saturday, December 7:
Sunday, December 8:
Monday, December 9 (embargoed until Tuesday 7:30 AM EST):
Late Breaking Abstract Session
Acute Lymphoblastic Leukemia (excluding Transplantation)
Therapeutic Strategies
Novel Therapies
Clinical Studies - Choice of Poster-Abstracts with Asparaginase
CAR T Cells--Refining the Approach
Chemo Immuno and Targets--Improving Combinations in ALL
Acute Myeloid Leukemia (excluding Transplantation)
Clinical Studies: Non-Intensive Therapy
Intensive Upfront Chemotherapy
Treatment of Relapsed/Refractory Disease
Induction and Post-Remission Therapy
New Treatment Strategies
Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs
Novel Targets and Combinations
Chronic Myeloid Leukemia: Therapy
Predictors of TKI Discontinuation and TFR Outcomes
Clinical Trials and Outcomes
Response Monitoring and Prognosis
Myeloproliferative Syndromes
Emerging and Novel Targeted Therapies
JAK Inhibitors and Combination Therapies
Myelodysplastic Syndromes
Combination Therapies
Targeting Gene Mutations in MDS
Lower-Risk MDS and CMML
SAKK POSTER
Myeloma: Therapy, excluding Transplantation
New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
Therapeutics Questions in Newly Diagnosed Myeloma
Improving the Outcomes of Newly Diagnosed Multiple Myeloma
Novel Therapy for Relapsed Myeloma
CLL (excluding Transplantation)
First Line Treatment
Combination and Novel Treatment
BTK Inhibitors and CAR T Cells in CLL
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
Follicular Lymphoma: Biomarkers and Clinical Trials
Clinical Trials in Waldestrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas
Mantle Cell Lymphoma: Frontline and Relapsed Therapies
Hodgkin Lymphoma and T/NK Cell Lymphoma
Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma
Immunotherapy Approaches in Hodgkin Lymphoma
Novel Therapies in Peripheral T-cell Lymphomas
Aggressive Lymphoma (DLBC and Other Aggressive B-Cell Non-Hodgkin Lymphomas
Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy
Results from Prospective Clinical Trials: Results from CAR T-Cell Trials
Novel Therapies in Relapsed/Refractory Disease
Results from Retrospective/Observational Studies: Population-Based Outcomes
Results from Retrospective/Observational Studies: Prognostic Markers
Results from Retrospective/Observational Studies: Cellular Therapies
Immunotherapies
Immunotherapies I
Immunotherapies II
Gene Therapy and Transfer
Advancing CAR T Cells: New Biology and Therapeutic Applications
Gene Therapies for Non-Malignant Disorders
CAR-T-Zell Therapie in der Schweiz
Archiv 2019
6th ICIS Expert Meeting on “Critical questions in immune thrombocytopenia in children and adults”
Welcome
Session 1
Session 2
Session 3
Session 4
8. Interdisziplinäres Prostatakarzinom-Symposium 2019
I Grundlagen und Früherkennung
II Lokoregionäre Therapie des Prostatakarzinoms
III Aspekte der Systemtherapie des Prostatakarzinoms
Cancer Academy – Immuntherapie
Jahrestagung 2019 von DGHO, OeGHO, SGMO und SGH+SSH
Pressekonferenz
OnkoZentrum Zürich - Patientenforum 2019
ESMO 2019
Press Briefings
Opening Press Conference
Lung and gynaecological cancers
Breast cancer
Gastrointestinal and genitourinary cancers
SAKK Studien am ESMO 2019
Brustkrebs
Gastrointestinal Cancers
Metastatic Colorectal Cancer (mCRC)
More from BEACON CRC & TAILOR
Metastatic Gastric, Pancreatic & Biliary Cancer
Lung Cancer, Mesothelioma & Head and Neck Cancer
Melanoma
Ovarialkarzinom
Cancer Academy - Kopf-Hals-Tumore
IASLC 2019 World Conference on Lung Cancer (#WCLC19)
Interviews
Press Briefings
Saturday, September 7th Press Briefing
Sunday, Sept. 8th Press Briefing
Monday, Sept 9th (Presidential Symposium Press Briefing)
Tuesday, Sept 10th Press Briefing
4th Zurich Immuno-Oncology Symposium
Keynote Address
Therapeutic Developments I
Therapeutic Developments II
Challenges in Patient Management
Challenges in Optimizing Treatment
Cell-based Therapies
ESMO World Congress on Gastrointestinal Cancer
Press Conferences (News being made available according embargo rules)
Wednesday, 3 July - Opening Press Conference
Thursday, 4 July - Key studies of the day
Friday, 5 July - Key studies of the day
Session II: Cancer of the Pancreas and Biliary Tract
Presentation of Selected GI Cancer Abstracts
Presentation of Selected Rectal Cancer Abstracts
Session VII: Gastric Cancer - Presentation of Selected Abstracts
Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 1
Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 2
Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 1
Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 2
Session XVI: Hepatocellular Cancer - Presentation of Selected Abstracts
Session XX: Colorectal Cancer (Part I) - Presentation of Selected Abstracts & Comments Roger von Moos and Thomas Winder
Second Zurich Lung Cancer Symposium
Lung Cancer Screening and Approach to Small Lesions
Molecular Pathology of Lung Cancer
Development in Stage III NSCLC Disease
The Improvement of Survival in Metastatic NSCLC
The Importance of Clinical Trials
Approach to Oligometastatic Disease
15th International Conference on Malignant Lymphoma (ICML)
Introductory Press Conference
PLENARY SESSION
MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?
HOW TO APPROACH CLL IN CLINICAL PRACTICE
THE MODERN APPROACH TO MANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA
PET IMAGING
PEDIATRIC LYMPHOMA
RESULTS FROM SINGLE AGENT TRIALS
ONGOING TRIALS
DLBCL: CLINICAL DATA
CLL
TREATMENT WITH NOVEL ANTIBODIES
T-CELL LYMPHOMAS
CLL AND MORE
CHEMOTHERAPY-FREE STRATEGIES
NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS
HIGH RISK LARGE B-CELL LYMPHOMAS
LYMPHOMA PATHOLOGY
HODGKIN LYMPHOMA
FOLLICULAR LYMPHOMA
EXTRANODAL LYMPHOMAS
NEW DATA ON T-CELL AND OTHER LYMPHOMAS
ADVANCES IN CAR T-CELL TREATMENT
NEW DRUG COMBINATIONS
INDOLENT NON-FOLLICULAR LYMPHOMA
24th Congress of EHA
Presidential Symposium
Late-breaking oral presentations (6 best abstracts)
Important presentations at Press Briefings
Friday, June 14, 2019
Saturday, June 15, 2019
Indolent and mantle-cell non-Hodgkin Lymphoma - clinical
Aggressive lymphomas - New agents
Aggressive lymphomas - First line, combination therapy and real-life data - Aggressive non-Hodgkin lymphoma
Hodgkin lymphoma - clinical
Novel agents and therapies for CLL
New stratification and treatment approaches in ALL - including CAR T Cell therapy
Advances in the management of thalassemia
Immunotherapy in relapsed/refractory multiple myeloma
Novel strategies in multiple myeloma
Novel agents for newly diagnosed plasma cell dyscrasias
Myeloma and other monoclonal gammopathies - Clinical
New therapies in AML
Gene therapy, cellular immunotherapy and vaccination - Biology & translational research
Gene therapy, cellular immunotherapy and vaccination - Clinical
Update on clinical trials in MPN
New agents in MPN
Annual Meeting of the American Society of Clinical Oncology 2019
Press Briefings
May 15 Presscast
Press Briefing Saturday June 1:
Press Briefing Sunday June 2:
Press Briefing Monday June 3:
Breast Cancer
Breast Cancer News Interviews
Breast Cancer News Aufzeichnung Live-Stream
Oral & Poster Presentations
Colon Cancer
Oral Presentations
Poster Presentations
Other gastrointestinal Cancer
Oral Presentations
Poster Presentations
Other Gynaecologic Cancers
Head & Neck Cancers
Oral Presentations
Poster Presentations
Lung Cancer
Hauttumore
Urogenital Cancers
Oral Presentations
Poster Presentations
Hematology
Multiple Myeloma & Myelofibrosis
Lymphoma & CLL
ALL
Senologie Update 2019
Teil 1:
Teil 2:
Teil 3:
Teil 4:
ELCC 2019 - European Lung Cancer Congress | ESMO 10-13 April 2019 Geneva, Switzerland
BCC2019
Opening and Award Ceremony:
Session 1: News since St.Gallen 2017
Session 2: Biology of Breast Cancer I: Risk stratification
Session 3: Biology of breast cancer II: Prediction of response
Session 4: Risk stratification and prevention in ductal in situ carcinoma
Special lecture I and II
Session 5: New pathways with potential impact in the treatment of early breast cancer
Session 6: Treatment tailoring according to pathology and biology
Session 7: Surgery of early breast cancer
Session 8: Radiotherapy of early breast cancer
Special lecture III
Session 9: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit I
Session 10: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit II
GenomicHealth interactive satellite symposium in conjunction with the 16th St Gallen International Breast Cancer Conference
Nanostring Satellite Symposium: Recent Breakthroughs for HR+/HER2- Early Breast Cancer Patients:
Interviews (in German): Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
Three SAKK Posters
45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Interviews
Presidential Symposium
GS2-2 - IMPROVED SURVIVAL OF AML- AND MDS-PATIENTS AFTER TREOSULFAN-BASED COMPARED TO REDUCED‑INTENSITY BUSULFAN-BASED CONDITIONING-REGIMEN FOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION: FINAL RESULTS OF A PROSPECTIVE RANDOMISED PHASE-III-TRIAL
GS2-3 - GRAFT-VERSUS-LEUKEMIA EFFECT AFTER HAPLO-IDENTICAL STEM-CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN AML- NO ASSOCIATION WITH GRAFT-VERSUS-HOST-DISEASE: A STUDY OF THE ACUTE LEUKEMIA WORKING PARTY OF EBMT
GS2-4 - SEQUENTIAL CD19- AND CD22-CART CELL THERAPIES FOR RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 10-MONTH MEDIAN FOLLOW-UP
GS2-5 - ALLOGENEIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS VERSUS MATCHED OR MISMATCHED 9/10 UNRELATED DONORS IN ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
GS2-6 - LOW-DOSE INFUSIONS OF CD45RA DEPLETED DONOR LYMPHOCYTES AFTER TCR ALPHA/BETA-DEPLETED TRANSPLANTATION IN PATIENTS WITH NON-MALIGNANT DISORDERS
GS2-7 - CELL-MEDIATED IMMUNOGENICITY OF THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) IN ADULT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED ZOE-HSCT CLINICAL TRIAL
Oral Session 9: Late-breaking abstracts
OS9-1 - COMPARABLE OUTCOME AFTER 10/10 AND 9/10 HLA-MATCHED UNRELATED DONOR STEM CELL TRANSPLANTATION (HSCT) USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR GVHD PROPHYLAXIS, ON BEHALF OF THE ALWP-EBMT.
OS9-2 - MYELOABLATIVE CONDITIONING FOR FIRST ALLOGENEIC HSCT IN PEDIATRIC ALL: FTBI OR CHEMOTHERAPY? - AN UPDATE OF THE RETROSPECTIVE MULTICENTER EBMT-PDWP STUDY
OS9-3 - THE DETECTION OF THE SOLUBLE EBV ZEBRA PROTEIN AS A NEW PREDICTIVE BIOMARKER FOR PTLD
OS9-4 - EFFECTIVE CANCER IMMUNOTHERAPY WITH ERBB2-CAR-ENGINEERED CYTOKINE-INDUCED KILLER (CIK) CELLS IN HIGH-RISK SOFT TISSUE SARCOMAS
OS9-5 - GENESIS - A PHASE III RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, EVALUATING SAFETY AND EFFICACY OF BL-8040 AND G-CSF IN MOBILIZATION OF HCS´S FOR AUTOLOGOUS TRANSPLANTATION-MULTIPLE MYELOMA
OS9-6 - REAL LIFE EXPERIENCE IN THE TREATMENT OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT ALL PATIENTS USING COMMERCIALLY AVAILABLE CAR-T-CELLS
How Do I... manufacture T cells for cellular therapies
HDI1-1 - Manufacturing of virus-specific T cells at an academic center
HDI1-2 - CAR T manufacturing in an academic setting
HDI1-3 - Low-dose memory T cell DLI for infection prophylaxis
How Do I... manage patients after CAR T-cell therapy.
HDI8-1 - Lymphoma, CLL and ALL
HDI8-2 - Myeloma patients
HDI8-3 - From a nurse's perspective
New developments in the field of CAR cell therapy
P2-1 - State of the art for ex-vivo manufactured autologous CAR T-cells
P2-2 - Simultaneous targeting of CD19 and CD22 with a bicistronic CAR - preliminary results of the AMELIA study
P2-3 - Off-the-shelf CAR NK cells for the treatment of hematologic malignancies
P2-4 - CAR T-cells against solid tumors: TRUCKs on the road
AGO MAMMAKARZINOM - State of the Art Meeting 2019
Vormittag 1
Vormittag 2
Nachmittag 1
Nachmittag 2
Interviews: Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
First Zürich Precision Oncology Symposium
Speakers
Molecular Testing and Molecular Tumor Board
Keynote address
Precision Oncology for Solid Tumors 1/Ongoing Research Activities 1
Precision Oncology for Solid Tumors 2
Precision Oncology for Hematologic Malignancies
Precision Oncology for Solid Tumors 2/Ongoing Research Activities 2
Archiv 2018
SABCS - 41st Annual San Antonio Breast Cancer Symposium
Press Conferences
Wednesday, Dec. 5, Press Conference 1
Wednesday, Dec. 5, Press Conference 2
Thursday, Dec. 6 Press Conference
Friday, Dec. 7 Press Conference
Schweizer Poster am SABCS
Interviews - Breast Cancer
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Achim Rody, Lübeck
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle/Saale
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Priv.-Doz. Dr. med. Hans-Christian Kolberg in Bottrop
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Sibylle Loibl, Frankfurt
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Michael Untch, Berlin-Buch
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. Rachel Würstlein, München
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Jörg Schilling, Berlin
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Priv.-Doz. Dr. med. Hans-Christian Kolberg, Bottrop
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Lothar Müller, Onkologie Unterems
Schweizer Expertenrunde mit einigen Highlights vom SABCS:
Round Table mit Brustkrebs Deutschland e.V.
General Sessions
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
GENERAL SESSION 5:
GENERAL SESSION 6:
American Society of Hematology (ASH) 60th Annual Meeting and Exposition
Statements & Opinions from some Highlights of the Conference
PD Dr. med. Nicolas Bonadies, Bern
Prof. Dr. med. Christoph Driessen, St. Gallen
Prof. Dr. med. Christoph Renner, Zürich
Press Briefings
Saturday December 1
Sunday December 2
Monday December 3
Late-Breaking Abstracts Session
Myeloma: Therapy and upfront autologous Transplantation
Novel Antibody Combinations in Myeloma
Novel Targeted Combinations in Myeloma
Antibodies and Targeted Therapies
Novel Proteasome Inhibitors
Immunotherapies in Plasma Cell Disorders
Immunotherapy
Upfront Autologous Transplantation
Choice of Myeloma Posters
AML
Acute Myeloid Leukemia - Clinical Studies
Acute Myeloid Leukemia - Commercially Available Therapy, excluding Transplantation:
Acute Myeloid Leukemia - Novel Therapy, excluding Transplantation
Lymphoma
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies
Acute Lymphoblastic Leukemia: Clinical Studies & Therapy Excluding Transplantations
Improving Outcomes with Cellular Therapy
Improving Frontline Therapy in ALL
Chimeric Antigen Receptor T-cell therapy in ALL: What Is Next?
Targeted Therapy in ALL: Immunotherapy and Beyond
CLL: Therapy, excluding Transplantation:
Measurable Residual Disease in CLL: Moving Towards a Cure
Cellular Therapy and Immunomodulation in CLL
Advances in CLL Using Novel Combination Therapy
Chronic Myeloid Leukemia: Therapy
Epidemiology, Prognosis, and Real Life Care
First Line Trials and Prognostic Factors of Treatment-Free Remission
TFR Failure, Resistance, and New Drug Development
Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics, Prognosis and Prediction
Novel Therapeutics I
Novel Therapeutics II
Prognosis and Prediction
Scientific, medical, clinical, relevant “asparaginase” related Presentations
Health Services & Outcome Research—Malignant Diseases
Clinical Trials for Hemophilia and Using CAR T Cells
Thalassemia and Globin Gene Regulation
Cancer Academy: Sarkome, Früherkennung, Diagnose und Behandlung
ESMO 2018 Congress
Press Briefings
Breast Cancer
Ovarian Cancer
Prostate & Kidney Cancers
Head & Neck Cancer
All ESMO 2018 Press Releases
Interviews
Interviews - Breast Cancer
Statement Summary GIT-Cancers
Statements Colorectal Cancer
Statements Gastric Cancer
Statements Lung Cancer
Statement Renal Cell Carcinoma
Links to selected presentations and abstracts
Presidential Sessions
Selection of Posters
Cancer Academy - Blut- und Lymphdrüsenkrebs
Comprehensive Cancer Center Zürich: Third Zurich Immuno-Oncology Symposium
Keynote address
Clinical results, patient cases and future developments I
Clinical results, patient cases and future developments II
Clinical results, patient cases and future developments III
Developments in immunotherapy
20th World Congress on Gastrointestinal Cancer (WCGIC 2018)
Session I: Welcome with Selected Abstracts
Session II: Cancer of the Pancreas and Biliary Tract - Selected Abstracts
Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer
Pancreatic Cancer: Poster Session
Session VII: Gastric Cancer: Presentation of selected abstracts
Session VIII: Diseases and Cancers of the Liver: Presentation of a selected abstract
Session XI: Presentation of Selected Abstracts: Colorectal Cancer
Session XX: Colorectal Cancer: Presentation of selected abstracts
23rd Congress of EHA
Presidential Symposium
Plenary Session Abstracts
Press Briefings
Press Briefing Day 1
Press Briefing Day 2
Important AML Presentations
IDHm and BCL2 inhibitors in AML
One AML Poster
Important CLL Presentations
Important Multiple Myeloma Presentations
Advances in front-line treatment of newly diagnosed multiple myeloma
New therapeutic strategies to improve the outcome of relapsed/refractory plasma cell disorders
Multiple Myeloma Poster Presentations
One Multiple Myeloma Late Breaking Abstract
Important Lymphoma Presentations
Thalassemia (2 Presentations) & MDS (1 Presentation)
ESMO Preceptorship on Colorectal Cancer 2018
SENOLOGIE update 2018
Prophylaktische Mastektomie - Moderation: M. Knauer, St. Gallen
Psychosoziale Konsequenzen des Mammakarzinoms - Moderation: E. Sarasin, Zürich
Update Systemtherapie - Moderation: U. Breitenstein, Zürich
Varia - Moderation: E. Saurenmann, Zürich
Cancer Academy - Darmkrebs
AACR Annual Meeting 2018, April 14-18,
Highlights presented at the Press Conference Sunday, April 15
Highlights presented at the Press Conference Monday, April 16
Highlights presented at the Press Conference Tuesday, April 17
ELCC 2018 (European Lung Cancer Congress)
Highlights - Press Releases
Interviews
Conference Highlights
Interviews in Cooperation with the Video Journal of Oncology - Part 1
SAKK 16/14 – Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
11th European Breast Cancer Conference (EBCC-11)
Press conferences
Important News
Interviews
PD Dr. med. Christian Kolberg, Bottrop
Prof. Dr. med. Thorsten Kühn, Esslingen
Prof. Dr. med. Nadia Harbeck, München
St. Gallen International Gastrointestinal Cancer Conference Primary Therapy of Early GI Cancers -
Session 1: Oesophago-Gastric Cancer: One Disease or Separate Entities?
Session 2: Treatment of Oesophago-Gastric Cancer: Setting the Stage – Who Benefits from Multimodal Therapy
Session 3: Treatment Modalities for Oesophago-Gastric Cancer
Session 4: Special situation I: Signet Ring Cell Cancer
Keynote: Hereditary Gastric Cancer
New Therapy Options by metastatic Colorectal Cancer
Session 5: Special situation II: Limits of Curative Approaches to Metastatic Oesophago-Gastric Cancer
Session 6: Ready for Practice?
EORTC Gastrointestinal Tract Cancer Group:
Cancer Academy - Prostatakrebs
Promoting Self-efficacy with Digital Tools
Welcome (German)
Promoting patients’ self-efficacy: How can it be successful? (German)
United Kingdom’s perspective on the use of digital solutions to improve cancer patients’ self-efficacy
Presentation of selected digital and patient-oriented applications
Consilium: Patient-centered communication for improved self-efficacy and quality of life
STREAM – Ein online Programm zur Unterstützung bei Belastung während einer Krebserkrankung
Symptom Navi: Förderung des Selbstmanagements von Symptomen bei Krebs
Entspannung und Achtsamkeit für Krebspatienten mit Hilfe einer App (CanRelax)
FertiOnco – an online approach to facilitate decision making in young female cancer patients regarding fertility preservation
The use of patient-reported outcomes to improve outcomes and quality in cancer care
Digital solutions for cancer patients: reach, (cost-) effectiveness and implementation
Discussion and Closing remarks (German)
Archiv 2017
59th ASH Annual Meeting and Exposition
Late-Breaking Abstracts Session
AML
Oral Sessions
Multiple Myeloma
Oral Sessions
Choice of Posters
Lymphoma
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
Hodgkin Lymphoma and T/NK Cell Lymphoma
CLL: Therapy, excluding Transplantation:
Press Conferences
Novel Approaches to Hemophilia and Venous Thromboembolism Care
Engineering Solutions to Treat Inherited Blood Disorders
Enhancing Care in Hematologic Malignancies through Targeted Therapies
Driving Outcomes in Lymphoma, Myeloma with CAR T-Cell Therapies
Late-Breaking Abstracts
Interviews
Statement Christian Taverna, Münsterlingen
Statement Thorsten Zenz, Zürich
40th Annual San Antonio Breast Cancer Symposium (SABCS)
General Sessions
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
GENERAL SESSION 5:
GENERAL SESSION 6:
Press Conferences
Wednesday December 6 @ 7:15 a.m.
Wednesday December 6 @ 12:15 p.m
Thursday December 7 @ 7:30 am
Friday December 8 @ 7:30 am
Interviews & Brustkrebs Deutschland Round Table & SAKK Roundtable
Roundtable Brustkrebs Deutschland
Roundtable mit Experten aus der Schweiz
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Peyman Hadji, Marburg
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Peyman Hadji, Marburg
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin (Kopie)
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Stefan Buchholz, Regensburg
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. phil. Ute Berndt, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr.med. Michael Untch, Berlin-Buch
Cancer Academy – Hirntumoren
7. Interdisziplinäres Prostatakarzinomsymposium
Grundlagen
Lokalisiertes & oligometastatisches Prostatakarzinom
Systemtherapien Prostatakarzinom
Advanced Breast Cancer 4th ESO-ESMO International Consensus Conference
Cancer Academy – Brustkrebs
ESMO 2017 Congress
Breast Cancer Highlights
Neoadjuvante Therapie bei luminalem, triple negativem oder HER2 positivem Brustkrebs
Luminaler Brustkrebs - wer braucht Chemotherapie?
CDK4-6 Inhibitoren beim metastasierten Brustkrebs
Abstract LBA10_PR ‘Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)’
Abstract 1472P_PR ‘Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients’
Gastrointestinal Carcinoma Highlights
Colorectal Cancer
Gastric Cancer
Head & Neck Cancer Highlights
PD Dr. med. Sacha Rothschild comments Head&Neck Cancer Studies
Abstract LBA45_PR ‘Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial’
1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
1. First line Cetuximab and Cisplatin with or without Paclitaxel/2. The observational ENCORE study: Cetuximab + platinum-based therapy
Lung Cancer Highlights
Prof. Martin Reck
PD Dr. AlessandraCurioni-Fontecedro
PD Dr. AlessandraCurioni-Fontecedro
Prof. Dr. med.Solange Peters
Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
Melanoma & Merkel Cell Carcinoma Highlights
Prof. Dr. med. Reinhard Dummer, Zurich
Prof. Dr. med. Olivier Michielin, Lausanne
Ovarian Cancer Highlights
Urogenital Cancer Highlights
Richard Cathomas, Chur, comments on the urogenital Carcinoma Highlights
Abstract LBA37_PR – ‘Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial’
Late breaking news
Opening Press Conference
LBA Press Conference: Lung cancer
Press Conference: Facing the challenges of life after cancer
LBA Press Conference: Breast cancer, Gynaecological cancers, Genito-urinary cancers
LBA Press Conference: Melanoma cancer
Wrap-Up press conference/Best of ESMO2017
Cancer Center Zürich Second - Zurich Immuno-Oncology Symposium
Welcome
Essentials of tumour immunology and immunotherapies
Clinical results, patient cases and future developments I
Clinical results, patient cases and future developments II
Clinical results, patient cases and future developments III
Management of toxicities
ESMO 19th World Congress on Gastrointestinal Cancer
Cancer of the Pancreas
Session II: Cancer of the Pancreas & bile Ducts
Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology
Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate
Interview mit Prof. Gerald Prager, Wien
Colon Cancer Highlights
Session XIX: Colorectal Cancer
Prof. Dr. med. Bernhard Pestalozzi, UniversitätsSpital Zürich:
Die besonderen Bedürfnisse von Kindern und Jugendlichen mit Krebs
14 The International Conference on Malignant Lymphoma (ICML)
Interviews & Introductory Press Conference
Introductory Press Conference
Lymphoma Therapy
Oncoletter Interviews in cooperation with VJHEMONC
Satellite Symposia
THE FIRST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE
CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?
ELCC 2017 Genf
Cancer Academy – Lungenkrebs: Früherkennung, Diagnose und Behandlung
SENOLOGIE update 2017
Radiologie - Moderation: F. Dammann, Zürich
Genetik - Moderation: R. Morant, Rapperswil
Qualitätssicherung in der Senologie - Moderation: C. Rageth, Zürich
Operative Therapie - Moderation: C. Tausch, Zürich
Das metastasierte Mammakarzionom - Moderation: A. Müller, Winterthur
Varia - Moderation: D. Fink, Zürich
15th St.Gallen International Breast Cancer Conference
Symposium Thoracic Oncology – Guidelines and Beyond
Screening
Inquiring the molecular tumor characteristics
Shanghai meets Zürich
Treatment options in localized NSCLC
Multimodality approaches in rare thoracic tumors
Metastatic disease
Livecasts & Kongresskalender
Livecast
Kongresskalender 2021
Kongresskalender 2022
Drugs oral & i.v., Guidelines, Interaktionen
Orale Krebstherapeutika
orale Wirkstoffe A
orale Wirkstoffe B
Orale Wirkstoffe C
Orale Wirkstoffe D
Orale Wirkstoffe E
Orale Wirkstoffe F
Orale Wirkstoffe G
Orale Wirkstoffe H
Orale Wirkstoffe I
Orale Wirkstoffe L
Orale Wirkstoffe Ν
Orale Wirkstoffe O
Orale Wirkstoffe P
Orale Wirkstoffe R
Orale Wirkstoffe S
Orale Wirkstoffe T
Orale Wirkstoffe U
Orale Wirkstoffe V
Orale Wirkstoffe Z
Alle Wirkstoffe
Melden Sie fehlende Wirkstoffe
Acronyme
ALK-Inhibitors
Wirkstoffe A
Wirkstoffe B
Wirkstoffe C
Wirkstoffe D
Wirkstoffe E
Wirkstoffe F
Wirkstoffe G
Wirkstoffe H
Wirkstoffe I
Wirkstoffe K
Wirkstoffe L
Wirkstoffe M
Wirkstoffe N
Wirkstoffe O
Wirkstoffe P
Wirkstoffe Q
Wirkstoffe R
Wirkstoffe S
Wirkstoffe T
Wirkstoffe U
Wirkstoffe V
Wirkstoffe Z
Behandlungsguidelines
The Cancer Cell Line Encyclopedia
Schweizer Krebsbulletin
Oncologic emergencies
Interaktionsprüfungen
Krebserkrankungen (Entstehung, Verlauf, Therapie & Prävention)
Wissenschaftlicher Beirat Oncoletter
Nebenwirkungen & Behandlungs- vorschläge
Symptome
Allgemeine Störungen
Fatigue
Fieber/Infektion
Ödeme
Schmerzen
Stimmungsschwankungen
Atmungsorgane
Dyspnoe
Epistaxis/Nasenbluten
Pleuraerguss
Augen
Konjunktivitis
Periorbitale Oedeme
Sehstoerungen
Blut- und Lymphsystem
Anaemie
Lymphopenie
Neutropenie
Thrombozytopenie
Gastrointestinale Störungen
Abdominalschmerz
Diarrhoe
Dyspepsie
Mukositis/Stomatitis
Nausea und Erbrechen
Obstipation
Haut
Aktinische Keratose
Alopezie
Hand-Fuss-Syndrom
Hyperkeratose
Photosensivitätsreaktion
Plattenepithelkarzinom der Haut
Praevention von Pruritus, Rash, Desquamation
Pruritus
Rash, papulopustulöse, follikuläre Exantheme
Seborrhoische Keratose
Sonnenbrand
Trockene Haut
Herz, Gefässe
Arterielle Hypertonie
Blutungen
Herzinsuffizienz
Hitzewallungen
Verminderung der linksventrikulären Auswurfsfraktion (LVEF)
Leber und Galle
Dosierungsempfehlungen oraler TKI/mTor-Inhibitoren bei Leberdysfunktion
Gamma-Glutamyl-Transferase
Muskelskelettsystem
Arthralgien
Knochenschmerzen
Muskelschwaeche
Muskelverhaertungen und Muskelkraempfe
Muskuloskelettale Beschwerden/Schmerzen in den Extremitaeten/Gliederschmerzen
Myalgie/Muskelschmerzen
Rueckenschmerzen
Nervensystem
Dysgeusie
Insomnie
Kopfschmerzen
Neuropathie/Polyneuropathie
Reversible posteriore Leukenzephalopathie
Niere und ableitende Harnwege
Harnwegsinfekt
Stoffwechsel- und Ernährungsstörungen
Amylase-/Lipasewerte
Anorexie
Cholesterol- oder Triglyzeridwerte
Gewichtszunahme
Glucosewerte
Hypokaliämie
Hypokalzämie
Hypophosphatämie
Hypothyreose
Referenzen
Nutzungsbestimmungen
Organisationen & Science Board
Science Board
Fachgesellschaften
Info für PatientINNen
Netzwerke
Navigation überspringen
Navigation/Menu
Navigation überspringen
Kongressberichte & Archiv
ESMO World Congress on Gastrointestinal Cancer 2021
Session I:
Session II:
Session IV:
Session V:
Session VI:
Session VII:
Session VIII:
Session IX:
Session X:
International Conference on Malignant Lymphoma (ICML)
PLENARY SESSION
SESSION 1:
SESSION 2:
SESSION 3:
SESSION 4:
SESSION 5
SESSION 6:
SESSION 7:
SESSION 8:
SESSION 9:
SESSION 10:
SESSION 11:
SESSION 12:
SESSION 13:
EHA2021 Virtual Congress
Presidential Symposium
Late-Breaking Oral Session
Acute leukemia
ALL - CAR-T: Alternative targets and age groups
ALL - Novel subgroups and agents
Developments in AML therapy
Chronic myeloid malignancies
Response, resistance and treatment-free remission in CML
Population based studies in myeloid disorders
Novel targets in MDS
New pathways and molecular mechanisms in MPN
Novel therapies and targets in MPN
Chronic lymphoid malignancies
Clinical trials with targeted therapies in CLL
New treatment strategies for newly diagnosed multiple myeloma
New diagnostic and therapeutic approaches in multiple myeloma and AL amyloidosis
T cell re-directing therapies in relapsed/refractory multiple myeloma
Lymphoma
Hodgkin lymphoma - Clinical
Indolent & mantle cell lymphoma - Clinical
Aggressive lymphoma - CAR-T & transplant
Aggressive lymphoma - Combination therapies
Immunology
Cellular immunotherapy and gene therapy - Clinical
Fungal, bacterial and viral infections in hematology
Red & white cell disorders
New directions in aplastic anemia and PNH
Stem cell transplantation - GvHD
Stem cell transplantation - Clinical
Changing the scene on sickle cell disease
Changing the scene on thalassemias
2021 ASCO Annual Meeting
Plenary Session (LBA's) & Presscast Presentations
Breast Cancer
Interviews
Früher Brustkrebs neoadjuvant: Talazoparib bei triple-negativer BRCA 1/2 Keimbahnmutation
#ASCO21: WSG-ADAPT HR+/HER2- Ergebnisse in der Hochrisikogruppe
#ASCO21: Neoadjuvante De-Eskalation in WSG-ADAPT HR-/HER2+
#ASCO21: Olaparib nach (neo)adjuvanter Chemotherapie bei Keimbahnmutation BRCA 1/2
#ASCO21: Bedeutung der CSF ctDNA beim triple-negativen Brustkrebs (neoadjuvant)
#ASCO21: GeparNUEVO - neoadjuvant Durvalumab beim triple-negativen Brustkrebs
#ASCO21: Highlights zum metastasierten Brustkrebs
#ASCO21: Patientenumfrage zur Dosisanpassung beim metastasierten Brustkrebs
#ASCO21: Brustkrebs Highlights local/regional/adjuvant
#ASCO21: Metastasierter hormonpositiver Brustkrebs - Update zu den CDK4/6 Inhibitoren
Breast Cancer—Local/Regional/Adjuvant
Breast Cancer—Local/Regional/Adjuvant
Breast Cancer—Metastatic
Breast Cancer—Metastatic
CNS Cancer
Central Nervous System Tumors
Central Nervous System Tumors
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Gastrointestinal Cancer
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Gastrointestinal Cancer—Colorectal and Anal
Gastrointestinal Cancer—Colorectal and Anal
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Gynaecological Cancer
Gynecologic Cancer
Gynecologic Cancer
Haematological Malignancies
Hematologic Malignancies—Plasma Cell Dyscrasia
Hematologic Malignancies—Plasma Cell Dyscrasia
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Head & Neck Cancer
Head and Neck Cancer
Head and Neck Cancer
Lung Cancer
Lung Cancer—Non-Small Cell Metastatic
Lung Cancer—Non-Small Cell Metastatic
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Melanoma/Merkel cell carcinoma
Sarcoma
Sarcoma
Sarcoma
Urogenital Cancer
Genitourinary Cancer—Kidney and Bladder
Genitourinary Cancer—Kidney and Bladder
Genitourinary Cancer—Prostate, Testicular, and Penile
Genitourinary Cancer—Prostate, Testicular, and Penile
American Association for Cancer Research (AACR) Annual Meeting 2021
Important Papers presented at the Press Conference
Important Papers presented in Press Releases
ELCC 2021
47th Annual Meeting of the European Society for Blood and Marrow Transplantation
Choice of oral Sessions
CART-T Cells 1
CART-T Cells 2
Multiple Myeloma
Choice Educational Sessions
CAR-T Toxicity and Management
CARs in Childhood Malignancy
New developments in the field of CAR cell therapy
Satellite Symposia
Present and future approaches with CAR T cell therapy in B-cell malignancies
Targeting the immune system in multiple myeloma: CAR T cell therapy and beyond
Brustkrebsinfotag 2021
News der Leitlinienkommission der AGO Mamma 2021
Archiv 2020
2020 San Antonio Breast Cancer Virtual Symposium
Press Briefing
Interviews geführt von Renate Haidinger, Brustkrebs Deutschland e.V.
Interview mit Ingo Bauerfeind, Landshut
Interview mit Nadia Harbeck, München
Interview mit Christian Jackisch, Offenburg
Interview mit Wolfgang Janni, Ulm
Interview mit Wolfgang Janni, Ulm
Interview mit Michael Patrick Lux, Würzburg
Interview mit Volkmar Müller, Hamburg
Interview mit Volkmar Müller, Hamburg
Interview mit Christoph Thomssen, Halle (Saale)
Interview mit Michael Untch, Berlin-Buch
Interview mit Michael Untch, Berlin-Buch
Interview mit Achim Wöckel, Würzburg
Interview mit Achim Wöckel, Würzburg
General Sessions
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
All-Virtual 62nd ASH Annual Meeting and Exposition
Press Briefings
Press Briefing on Disparities in Health Care: Diversity, Equity, and Inclusion (DEI)
Press Briefing on What’s on the Horizon: Practice-Changing Clinical Trials
Press Briefing on Hematologic Aspects of the Pandemic: Advancing the Study of COVID-19
Press Briefing on Advancing New Frontiers: Genome Editing & Cellular Therapy
Press Briefing on Selected Late-Breaking Abstracts
Plenary Scientific Session
Late-Breaking Abstracts Session
Choice of two Scientific Workshops on Lymphoid Malignancies
Scientific Workshop on Tumor Immune Interactions
Scientific Workshop on Tumor Immune Interactions
Satellite Symposia
Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management
Medical Crossfire®:Exploring the Modern Management of Acute Lymphoblastic Leukemia from AYA to Adult
A Fresh Look at CAR T-Cell Therapy: Recent Advances, New Evidence, and Evolving Paradigms to Improve Patient Care
Oral Sessions
Hemoglobinopathies
Coagulation & Platelet Disorders
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
Hodgkin Lymphoma and T/NK Cell Lymphoma
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
Chronic Myeloid Leukemia
Myeloproliferative Syndromes
Myelodysplastic Syndromes
CLL
Myeloma/Amyloidosis: Therapy excluding Transplantation:
52th Congress of the International Society of Paediatric Oncology (SIOP)
Sessions Highlights
Wednesday
Thursday
Friday
Saturday
Building Bridges to ensure best possible outcomes for children and adults with ALL
DGHO, OeGHO, SGMO und SGH+SSH Jahrestagung 2020 VIRTUAL
Best Abstracts
Innovative Hämatologie
EBCC-12 European Breast Cancer Conference
ESMO VIRTUAL 2020
Presidential Symposia
Presidential Symposium I
Presidential Symposium II
Presidential Symposium III
Breast cancer
Interviews
Proffered Paper - Breast cancer, early stage
Proffered Paper - Breast cancer, metastatic 1
Proffered Paper - Breast cancer, metastatic 2
Thoracic Cancer
Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies
Proffered Paper - NSCLC metastatic 1
Proffered Paper - NSCLC metastatic 2
CNS- & Skin Tumours, NETs & Sarcoma
Proffered Paper - NETs
Proffered Paper - Sarcoma
Proffered Paper - CNS tumours
Proffered Paper - Melanoma and other skin tumours
GU Tumours
Proffered Paper - GU, non prostate 1
Proffered Paper - GU, non prostate 2
Proffered Paper - GU, prostate
Gynaecological Cancers
Proffered Paper 1 - Gynaecological cancers
Proffered Paper 2 - Gynaecological cancers
Head & Neck & GI Cancers
Proffered Paper - Head & Neck cancer
Proffered Paper - GI, colorectal
Proffered Paper - GI, non colorectal
Immunotherapy, Translational Research & Basic Science
Proffered Papers - Investigational immunotherapy
Proffered Papers - Developmental therapeutics
Proffered Papers - Basic Science
Proffered Papers - Translational research
SARS-CoV-2 & Cancer
Proffered Paper - SARS-CoV-2 and cancer 1
Proffered Paper - SARS-CoV-2 and cancer 2
Supportive & Palliative Therapy, Public Policy
Proffered Paper - Supportive and palliative care
Proffered Paper - Public Policy
ESMO VIRTUAL CONGRESS 2020
VIRTUAL EBMT 46th Annual Meeting 2020
CAR-based Cellular Therapy
ACUTE LYMPHOBLASTIC LEUKEMIA
LARGE B-CELL LYMPHOMA
NON-HODGKIN LYMPHOMA
MULTIPLE MYELOMA
SIDE EFFECTS
MISCELLANEOUS
IASLC 21st World Conference on Lung Cancer
The 22nd ESMO World Congress on Gastrointestinal Cancer - Virtual Congress
Session I: Cancer of the Pancreas and Biliary Tract
Session II: Hepatocellular Cancer
Session III: Esophageal and Gastric Cancer
Session IV: Gastrointestinal Stromal Tumors (GIST); Neuroendocrine Tumors (NET)
Session V: Molecular Screening; Imaging; Artificial Intelligence
Session VI: Colorectal Cancer I
Session VII: Colorectal Cancer II
Session IX: Rectal Cancer
Virtual Edition of the 25th Annual Congress of the European Hematology Association
Presidential Symposium
Plenary Session I
Plenary Session II
Late-Breaking Oral Session - available fromSaturday June 13 8.30 AM
Oral Sessions
Acute Leukemia
Lymphoma
Chronic Myeloid Neoplasms
Chronic Lymphoid Neoplasms
Immunology
Red & White Cell Disorders
ITP:
Link to Satellite Session - Live Fri 12 Jun 17:30-18:30
e-Poster Presentations
ASCO20 Virtual Scientific Meeting
Studies presented at press briefings
Pre-Meeting Presentation
Press Briefing May 28
Plenary Session Abstracts
Oral Sessions
Breast Cancer I
Breast Cancer II
Brustkrebs Interviews
Gynecologic Cancer
Gynäkologische Karzinomata - Interviews
SAMO Virtual Workshop on COVID19:
Coronavirus/Brustkrebs
AGO MAMMAKARZINOM - State of the Art Meeting 2020
Keynote-Lecture: Fatima Cardoso
Vormittag 1
Vormittag 2
Nachmittag 1
Nachmittag 2
Interviews im Rahmen einer Kooperation von Oncoletter mit Brustkrebs Deutschland e.v.
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Andreas Schneeweiss, Heidelberg, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Volkmar Müller, Hamburg und Wolfgang Janni, Ulm, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Diana Lüftner Berlin, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Christian Jackisch, Offenbach & Andreas Schneeweiss, Heidelberg, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Bernd Gerber, Rostock zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Volkmar Müller und Ute-Susann Albert, Frankfurt, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Achim Rody, Lübeck, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Achim Wöckel, Würzburg und Christoph Thomssen, Halle zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Michael Lux, Erlangen, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit David Krug, Kiel, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Christoph Thomssen, Halle, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Nina Ditsch, München, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Marc Thill, Frankfurt und Michael Untch, Berlin, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Tanja Fehm, Düsseldorf und Elmar Stickeler, Aachen, zum Thema:
Gespräch mit Kerstin Rhiem, Köln, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Jens Huober, Ulm, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Thorsten Kühn, Esslingen und Jens Uwe Blohmer, Berlin, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Hans H. Kreipe, Hannover, zum Thema:
Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Ingo Bauerfeind, Landshut und Nina Ditsch, München, zum Thema:
Ten Years of ETOP
2nd Zurich Brain Metastasis Symposium
Experimental Studies
Keynote Lectures
Updates on Therapeutic Approaches
Brain Metastasis: Disease Updates
Controversies & Hot Topics in the Diagnosis and Management of CNS Metastasis
SABCS - 42nd Annual San Antonio Breast Cancer Symposium
Press Conferences
Wednesday, Dec. 11
Thursday, Dec. 12
Friday, Dec. 13
General Sessions 1-6
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
GENERAL SESSION 5:
GENERAL SESSION 6:
Interviews - Breast Cancer
HER 2-positiver, metastasierter Brustkrebs: HER2CLIMB Studie mit Tucatinib
HER 2-positiver, metastasierter Brustkrebs: DESTINY-Breast01 Studie mit Trastuzumab Deruxtecan
HER 2-positiver Brustkrebs adjuvant: APHINITY Studie, 2. Zwischenanalyse
HER 2-positiver Brustkrebs adjuvant: ATEMPT Studie T-DM1 gegen Paclitaxel plus Trastuzumab
Einsatz von Capecitabine Neo/Adjuvant
GEPARX Studie: Denosumab im Vergleich zu zwei Nab-Paclitaxel Schemata - neoadjuvant
Immuncheckpoint-Inhibitoren: Durvalumab beim metastasierten BC und Pembrolizumab neoadjuvant und adjuvant bei TNBC
pCR bei neoadjuvanter Therapie mit Atezolizumab beim TNBC?
Neues zu CDK4/6 Inhibitoren (HR+ & HER2-)
Wenn der Brust-Tumor weg ist nach neoadjuvanter Therapie: Muss noch operiert werden?
Teil- oder Ganzbrustbestrahlung nach Brust erhaltender Therapie. Was für wen?
Schweizer Expertenrunde mit einigen Highlights vom SABCS:
Round Table mit Brustkrebs Deutschland e.V.
61st ASH Annual Meeting and Exposition
Highlights of the Conference: Statements & Opinions
ALL
Multiples Myelom
Multiples Myelom
Lymphome
Press Briefings
Saturday, December 7:
Saturday, December 7:
Saturday, December 7:
Sunday, December 8:
Monday, December 9 (embargoed until Tuesday 7:30 AM EST):
Late Breaking Abstract Session
Acute Lymphoblastic Leukemia (excluding Transplantation)
Therapeutic Strategies
Novel Therapies
Clinical Studies - Choice of Poster-Abstracts with Asparaginase
CAR T Cells--Refining the Approach
Chemo Immuno and Targets--Improving Combinations in ALL
Acute Myeloid Leukemia (excluding Transplantation)
Clinical Studies: Non-Intensive Therapy
Intensive Upfront Chemotherapy
Treatment of Relapsed/Refractory Disease
Induction and Post-Remission Therapy
New Treatment Strategies
Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs
Novel Targets and Combinations
Chronic Myeloid Leukemia: Therapy
Predictors of TKI Discontinuation and TFR Outcomes
Clinical Trials and Outcomes
Response Monitoring and Prognosis
Myeloproliferative Syndromes
Emerging and Novel Targeted Therapies
JAK Inhibitors and Combination Therapies
Myelodysplastic Syndromes
Combination Therapies
Targeting Gene Mutations in MDS
Lower-Risk MDS and CMML
SAKK POSTER
Myeloma: Therapy, excluding Transplantation
New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
Therapeutics Questions in Newly Diagnosed Myeloma
Improving the Outcomes of Newly Diagnosed Multiple Myeloma
Novel Therapy for Relapsed Myeloma
CLL (excluding Transplantation)
First Line Treatment
Combination and Novel Treatment
BTK Inhibitors and CAR T Cells in CLL
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
Follicular Lymphoma: Biomarkers and Clinical Trials
Clinical Trials in Waldestrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas
Mantle Cell Lymphoma: Frontline and Relapsed Therapies
Hodgkin Lymphoma and T/NK Cell Lymphoma
Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma
Immunotherapy Approaches in Hodgkin Lymphoma
Novel Therapies in Peripheral T-cell Lymphomas
Aggressive Lymphoma (DLBC and Other Aggressive B-Cell Non-Hodgkin Lymphomas
Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy
Results from Prospective Clinical Trials: Results from CAR T-Cell Trials
Novel Therapies in Relapsed/Refractory Disease
Results from Retrospective/Observational Studies: Population-Based Outcomes
Results from Retrospective/Observational Studies: Prognostic Markers
Results from Retrospective/Observational Studies: Cellular Therapies
Immunotherapies
Immunotherapies I
Immunotherapies II
Gene Therapy and Transfer
Advancing CAR T Cells: New Biology and Therapeutic Applications
Gene Therapies for Non-Malignant Disorders
CAR-T-Zell Therapie in der Schweiz
Archiv 2019
6th ICIS Expert Meeting on “Critical questions in immune thrombocytopenia in children and adults”
Welcome
Session 1
Session 2
Session 3
Session 4
8. Interdisziplinäres Prostatakarzinom-Symposium 2019
I Grundlagen und Früherkennung
II Lokoregionäre Therapie des Prostatakarzinoms
III Aspekte der Systemtherapie des Prostatakarzinoms
Cancer Academy – Immuntherapie
Jahrestagung 2019 von DGHO, OeGHO, SGMO und SGH+SSH
Pressekonferenz
OnkoZentrum Zürich - Patientenforum 2019
ESMO 2019
Press Briefings
Opening Press Conference
Lung and gynaecological cancers
Breast cancer
Gastrointestinal and genitourinary cancers
SAKK Studien am ESMO 2019
Brustkrebs
Gastrointestinal Cancers
Metastatic Colorectal Cancer (mCRC)
More from BEACON CRC & TAILOR
Metastatic Gastric, Pancreatic & Biliary Cancer
Lung Cancer, Mesothelioma & Head and Neck Cancer
Melanoma
Ovarialkarzinom
Cancer Academy - Kopf-Hals-Tumore
IASLC 2019 World Conference on Lung Cancer (#WCLC19)
Interviews
Press Briefings
Saturday, September 7th Press Briefing
Sunday, Sept. 8th Press Briefing
Monday, Sept 9th (Presidential Symposium Press Briefing)
Tuesday, Sept 10th Press Briefing
4th Zurich Immuno-Oncology Symposium
Keynote Address
Therapeutic Developments I
Therapeutic Developments II
Challenges in Patient Management
Challenges in Optimizing Treatment
Cell-based Therapies
ESMO World Congress on Gastrointestinal Cancer
Press Conferences (News being made available according embargo rules)
Wednesday, 3 July - Opening Press Conference
Thursday, 4 July - Key studies of the day
Friday, 5 July - Key studies of the day
Session II: Cancer of the Pancreas and Biliary Tract
Presentation of Selected GI Cancer Abstracts
Presentation of Selected Rectal Cancer Abstracts
Session VII: Gastric Cancer - Presentation of Selected Abstracts
Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 1
Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 2
Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 1
Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 2
Session XVI: Hepatocellular Cancer - Presentation of Selected Abstracts
Session XX: Colorectal Cancer (Part I) - Presentation of Selected Abstracts & Comments Roger von Moos and Thomas Winder
Second Zurich Lung Cancer Symposium
Lung Cancer Screening and Approach to Small Lesions
Molecular Pathology of Lung Cancer
Development in Stage III NSCLC Disease
The Improvement of Survival in Metastatic NSCLC
The Importance of Clinical Trials
Approach to Oligometastatic Disease
15th International Conference on Malignant Lymphoma (ICML)
Introductory Press Conference
PLENARY SESSION
MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?
HOW TO APPROACH CLL IN CLINICAL PRACTICE
THE MODERN APPROACH TO MANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA
PET IMAGING
PEDIATRIC LYMPHOMA
RESULTS FROM SINGLE AGENT TRIALS
ONGOING TRIALS
DLBCL: CLINICAL DATA
CLL
TREATMENT WITH NOVEL ANTIBODIES
T-CELL LYMPHOMAS
CLL AND MORE
CHEMOTHERAPY-FREE STRATEGIES
NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS
HIGH RISK LARGE B-CELL LYMPHOMAS
LYMPHOMA PATHOLOGY
HODGKIN LYMPHOMA
FOLLICULAR LYMPHOMA
EXTRANODAL LYMPHOMAS
NEW DATA ON T-CELL AND OTHER LYMPHOMAS
ADVANCES IN CAR T-CELL TREATMENT
NEW DRUG COMBINATIONS
INDOLENT NON-FOLLICULAR LYMPHOMA
24th Congress of EHA
Presidential Symposium
Late-breaking oral presentations (6 best abstracts)
Important presentations at Press Briefings
Friday, June 14, 2019
Saturday, June 15, 2019
Indolent and mantle-cell non-Hodgkin Lymphoma - clinical
Aggressive lymphomas - New agents
Aggressive lymphomas - First line, combination therapy and real-life data - Aggressive non-Hodgkin lymphoma
Hodgkin lymphoma - clinical
Novel agents and therapies for CLL
New stratification and treatment approaches in ALL - including CAR T Cell therapy
Advances in the management of thalassemia
Immunotherapy in relapsed/refractory multiple myeloma
Novel strategies in multiple myeloma
Novel agents for newly diagnosed plasma cell dyscrasias
Myeloma and other monoclonal gammopathies - Clinical
New therapies in AML
Gene therapy, cellular immunotherapy and vaccination - Biology & translational research
Gene therapy, cellular immunotherapy and vaccination - Clinical
Update on clinical trials in MPN
New agents in MPN
Annual Meeting of the American Society of Clinical Oncology 2019
Press Briefings
May 15 Presscast
Press Briefing Saturday June 1:
Press Briefing Sunday June 2:
Press Briefing Monday June 3:
Breast Cancer
Breast Cancer News Interviews
Breast Cancer News Aufzeichnung Live-Stream
Oral & Poster Presentations
Colon Cancer
Oral Presentations
Poster Presentations
Other gastrointestinal Cancer
Oral Presentations
Poster Presentations
Other Gynaecologic Cancers
Head & Neck Cancers
Oral Presentations
Poster Presentations
Lung Cancer
Hauttumore
Urogenital Cancers
Oral Presentations
Poster Presentations
Hematology
Multiple Myeloma & Myelofibrosis
Lymphoma & CLL
ALL
Senologie Update 2019
Teil 1:
Teil 2:
Teil 3:
Teil 4:
ELCC 2019 - European Lung Cancer Congress | ESMO 10-13 April 2019 Geneva, Switzerland
BCC2019
Opening and Award Ceremony:
Session 1: News since St.Gallen 2017
Session 2: Biology of Breast Cancer I: Risk stratification
Session 3: Biology of breast cancer II: Prediction of response
Session 4: Risk stratification and prevention in ductal in situ carcinoma
Special lecture I and II
Session 5: New pathways with potential impact in the treatment of early breast cancer
Session 6: Treatment tailoring according to pathology and biology
Session 7: Surgery of early breast cancer
Session 8: Radiotherapy of early breast cancer
Special lecture III
Session 9: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit I
Session 10: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit II
GenomicHealth interactive satellite symposium in conjunction with the 16th St Gallen International Breast Cancer Conference
Nanostring Satellite Symposium: Recent Breakthroughs for HR+/HER2- Early Breast Cancer Patients:
Interviews (in German): Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
Three SAKK Posters
45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
Interviews
Presidential Symposium
GS2-2 - IMPROVED SURVIVAL OF AML- AND MDS-PATIENTS AFTER TREOSULFAN-BASED COMPARED TO REDUCED‑INTENSITY BUSULFAN-BASED CONDITIONING-REGIMEN FOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION: FINAL RESULTS OF A PROSPECTIVE RANDOMISED PHASE-III-TRIAL
GS2-3 - GRAFT-VERSUS-LEUKEMIA EFFECT AFTER HAPLO-IDENTICAL STEM-CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN AML- NO ASSOCIATION WITH GRAFT-VERSUS-HOST-DISEASE: A STUDY OF THE ACUTE LEUKEMIA WORKING PARTY OF EBMT
GS2-4 - SEQUENTIAL CD19- AND CD22-CART CELL THERAPIES FOR RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 10-MONTH MEDIAN FOLLOW-UP
GS2-5 - ALLOGENEIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS VERSUS MATCHED OR MISMATCHED 9/10 UNRELATED DONORS IN ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
GS2-6 - LOW-DOSE INFUSIONS OF CD45RA DEPLETED DONOR LYMPHOCYTES AFTER TCR ALPHA/BETA-DEPLETED TRANSPLANTATION IN PATIENTS WITH NON-MALIGNANT DISORDERS
GS2-7 - CELL-MEDIATED IMMUNOGENICITY OF THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) IN ADULT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED ZOE-HSCT CLINICAL TRIAL
Oral Session 9: Late-breaking abstracts
OS9-1 - COMPARABLE OUTCOME AFTER 10/10 AND 9/10 HLA-MATCHED UNRELATED DONOR STEM CELL TRANSPLANTATION (HSCT) USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR GVHD PROPHYLAXIS, ON BEHALF OF THE ALWP-EBMT.
OS9-2 - MYELOABLATIVE CONDITIONING FOR FIRST ALLOGENEIC HSCT IN PEDIATRIC ALL: FTBI OR CHEMOTHERAPY? - AN UPDATE OF THE RETROSPECTIVE MULTICENTER EBMT-PDWP STUDY
OS9-3 - THE DETECTION OF THE SOLUBLE EBV ZEBRA PROTEIN AS A NEW PREDICTIVE BIOMARKER FOR PTLD
OS9-4 - EFFECTIVE CANCER IMMUNOTHERAPY WITH ERBB2-CAR-ENGINEERED CYTOKINE-INDUCED KILLER (CIK) CELLS IN HIGH-RISK SOFT TISSUE SARCOMAS
OS9-5 - GENESIS - A PHASE III RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, EVALUATING SAFETY AND EFFICACY OF BL-8040 AND G-CSF IN MOBILIZATION OF HCS´S FOR AUTOLOGOUS TRANSPLANTATION-MULTIPLE MYELOMA
OS9-6 - REAL LIFE EXPERIENCE IN THE TREATMENT OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT ALL PATIENTS USING COMMERCIALLY AVAILABLE CAR-T-CELLS
How Do I... manufacture T cells for cellular therapies
HDI1-1 - Manufacturing of virus-specific T cells at an academic center
HDI1-2 - CAR T manufacturing in an academic setting
HDI1-3 - Low-dose memory T cell DLI for infection prophylaxis
How Do I... manage patients after CAR T-cell therapy.
HDI8-1 - Lymphoma, CLL and ALL
HDI8-2 - Myeloma patients
HDI8-3 - From a nurse's perspective
New developments in the field of CAR cell therapy
P2-1 - State of the art for ex-vivo manufactured autologous CAR T-cells
P2-2 - Simultaneous targeting of CD19 and CD22 with a bicistronic CAR - preliminary results of the AMELIA study
P2-3 - Off-the-shelf CAR NK cells for the treatment of hematologic malignancies
P2-4 - CAR T-cells against solid tumors: TRUCKs on the road
AGO MAMMAKARZINOM - State of the Art Meeting 2019
Vormittag 1
Vormittag 2
Nachmittag 1
Nachmittag 2
Interviews: Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
First Zürich Precision Oncology Symposium
Speakers
Molecular Testing and Molecular Tumor Board
Keynote address
Precision Oncology for Solid Tumors 1/Ongoing Research Activities 1
Precision Oncology for Solid Tumors 2
Precision Oncology for Hematologic Malignancies
Precision Oncology for Solid Tumors 2/Ongoing Research Activities 2
Archiv 2018
SABCS - 41st Annual San Antonio Breast Cancer Symposium
Press Conferences
Wednesday, Dec. 5, Press Conference 1
Wednesday, Dec. 5, Press Conference 2
Thursday, Dec. 6 Press Conference
Friday, Dec. 7 Press Conference
Schweizer Poster am SABCS
Interviews - Breast Cancer
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Achim Rody, Lübeck
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle/Saale
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Priv.-Doz. Dr. med. Hans-Christian Kolberg in Bottrop
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Sibylle Loibl, Frankfurt
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Michael Untch, Berlin-Buch
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. Rachel Würstlein, München
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Jörg Schilling, Berlin
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Priv.-Doz. Dr. med. Hans-Christian Kolberg, Bottrop
Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Lothar Müller, Onkologie Unterems
Schweizer Expertenrunde mit einigen Highlights vom SABCS:
Round Table mit Brustkrebs Deutschland e.V.
General Sessions
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
GENERAL SESSION 5:
GENERAL SESSION 6:
American Society of Hematology (ASH) 60th Annual Meeting and Exposition
Statements & Opinions from some Highlights of the Conference
PD Dr. med. Nicolas Bonadies, Bern
Prof. Dr. med. Christoph Driessen, St. Gallen
Prof. Dr. med. Christoph Renner, Zürich
Press Briefings
Saturday December 1
Sunday December 2
Monday December 3
Late-Breaking Abstracts Session
Myeloma: Therapy and upfront autologous Transplantation
Novel Antibody Combinations in Myeloma
Novel Targeted Combinations in Myeloma
Antibodies and Targeted Therapies
Novel Proteasome Inhibitors
Immunotherapies in Plasma Cell Disorders
Immunotherapy
Upfront Autologous Transplantation
Choice of Myeloma Posters
AML
Acute Myeloid Leukemia - Clinical Studies
Acute Myeloid Leukemia - Commercially Available Therapy, excluding Transplantation:
Acute Myeloid Leukemia - Novel Therapy, excluding Transplantation
Lymphoma
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies
Acute Lymphoblastic Leukemia: Clinical Studies & Therapy Excluding Transplantations
Improving Outcomes with Cellular Therapy
Improving Frontline Therapy in ALL
Chimeric Antigen Receptor T-cell therapy in ALL: What Is Next?
Targeted Therapy in ALL: Immunotherapy and Beyond
CLL: Therapy, excluding Transplantation:
Measurable Residual Disease in CLL: Moving Towards a Cure
Cellular Therapy and Immunomodulation in CLL
Advances in CLL Using Novel Combination Therapy
Chronic Myeloid Leukemia: Therapy
Epidemiology, Prognosis, and Real Life Care
First Line Trials and Prognostic Factors of Treatment-Free Remission
TFR Failure, Resistance, and New Drug Development
Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics, Prognosis and Prediction
Novel Therapeutics I
Novel Therapeutics II
Prognosis and Prediction
Scientific, medical, clinical, relevant “asparaginase” related Presentations
Health Services & Outcome Research—Malignant Diseases
Clinical Trials for Hemophilia and Using CAR T Cells
Thalassemia and Globin Gene Regulation
Cancer Academy: Sarkome, Früherkennung, Diagnose und Behandlung
ESMO 2018 Congress
Press Briefings
Breast Cancer
Ovarian Cancer
Prostate & Kidney Cancers
Head & Neck Cancer
All ESMO 2018 Press Releases
Interviews
Interviews - Breast Cancer
Statement Summary GIT-Cancers
Statements Colorectal Cancer
Statements Gastric Cancer
Statements Lung Cancer
Statement Renal Cell Carcinoma
Links to selected presentations and abstracts
Presidential Sessions
Selection of Posters
Cancer Academy - Blut- und Lymphdrüsenkrebs
Comprehensive Cancer Center Zürich: Third Zurich Immuno-Oncology Symposium
Keynote address
Clinical results, patient cases and future developments I
Clinical results, patient cases and future developments II
Clinical results, patient cases and future developments III
Developments in immunotherapy
20th World Congress on Gastrointestinal Cancer (WCGIC 2018)
Session I: Welcome with Selected Abstracts
Session II: Cancer of the Pancreas and Biliary Tract - Selected Abstracts
Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer
Pancreatic Cancer: Poster Session
Session VII: Gastric Cancer: Presentation of selected abstracts
Session VIII: Diseases and Cancers of the Liver: Presentation of a selected abstract
Session XI: Presentation of Selected Abstracts: Colorectal Cancer
Session XX: Colorectal Cancer: Presentation of selected abstracts
23rd Congress of EHA
Presidential Symposium
Plenary Session Abstracts
Press Briefings
Press Briefing Day 1
Press Briefing Day 2
Important AML Presentations
IDHm and BCL2 inhibitors in AML
One AML Poster
Important CLL Presentations
Important Multiple Myeloma Presentations
Advances in front-line treatment of newly diagnosed multiple myeloma
New therapeutic strategies to improve the outcome of relapsed/refractory plasma cell disorders
Multiple Myeloma Poster Presentations
One Multiple Myeloma Late Breaking Abstract
Important Lymphoma Presentations
Thalassemia (2 Presentations) & MDS (1 Presentation)
ESMO Preceptorship on Colorectal Cancer 2018
SENOLOGIE update 2018
Prophylaktische Mastektomie - Moderation: M. Knauer, St. Gallen
Psychosoziale Konsequenzen des Mammakarzinoms - Moderation: E. Sarasin, Zürich
Update Systemtherapie - Moderation: U. Breitenstein, Zürich
Varia - Moderation: E. Saurenmann, Zürich
Cancer Academy - Darmkrebs
AACR Annual Meeting 2018, April 14-18,
Highlights presented at the Press Conference Sunday, April 15
Highlights presented at the Press Conference Monday, April 16
Highlights presented at the Press Conference Tuesday, April 17
ELCC 2018 (European Lung Cancer Congress)
Highlights - Press Releases
Interviews
Conference Highlights
Interviews in Cooperation with the Video Journal of Oncology - Part 1
SAKK 16/14 – Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
11th European Breast Cancer Conference (EBCC-11)
Press conferences
Important News
Interviews
PD Dr. med. Christian Kolberg, Bottrop
Prof. Dr. med. Thorsten Kühn, Esslingen
Prof. Dr. med. Nadia Harbeck, München
St. Gallen International Gastrointestinal Cancer Conference Primary Therapy of Early GI Cancers -
Session 1: Oesophago-Gastric Cancer: One Disease or Separate Entities?
Session 2: Treatment of Oesophago-Gastric Cancer: Setting the Stage – Who Benefits from Multimodal Therapy
Session 3: Treatment Modalities for Oesophago-Gastric Cancer
Session 4: Special situation I: Signet Ring Cell Cancer
Keynote: Hereditary Gastric Cancer
New Therapy Options by metastatic Colorectal Cancer
Session 5: Special situation II: Limits of Curative Approaches to Metastatic Oesophago-Gastric Cancer
Session 6: Ready for Practice?
EORTC Gastrointestinal Tract Cancer Group:
Cancer Academy - Prostatakrebs
Promoting Self-efficacy with Digital Tools
Welcome (German)
Promoting patients’ self-efficacy: How can it be successful? (German)
United Kingdom’s perspective on the use of digital solutions to improve cancer patients’ self-efficacy
Presentation of selected digital and patient-oriented applications
Consilium: Patient-centered communication for improved self-efficacy and quality of life
STREAM – Ein online Programm zur Unterstützung bei Belastung während einer Krebserkrankung
Symptom Navi: Förderung des Selbstmanagements von Symptomen bei Krebs
Entspannung und Achtsamkeit für Krebspatienten mit Hilfe einer App (CanRelax)
FertiOnco – an online approach to facilitate decision making in young female cancer patients regarding fertility preservation
The use of patient-reported outcomes to improve outcomes and quality in cancer care
Digital solutions for cancer patients: reach, (cost-) effectiveness and implementation
Discussion and Closing remarks (German)
Archiv 2017
59th ASH Annual Meeting and Exposition
Late-Breaking Abstracts Session
AML
Oral Sessions
Multiple Myeloma
Oral Sessions
Choice of Posters
Lymphoma
Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
Hodgkin Lymphoma and T/NK Cell Lymphoma
CLL: Therapy, excluding Transplantation:
Press Conferences
Novel Approaches to Hemophilia and Venous Thromboembolism Care
Engineering Solutions to Treat Inherited Blood Disorders
Enhancing Care in Hematologic Malignancies through Targeted Therapies
Driving Outcomes in Lymphoma, Myeloma with CAR T-Cell Therapies
Late-Breaking Abstracts
Interviews
Statement Christian Taverna, Münsterlingen
Statement Thorsten Zenz, Zürich
40th Annual San Antonio Breast Cancer Symposium (SABCS)
General Sessions
GENERAL SESSION 1:
GENERAL SESSION 2:
GENERAL SESSION 3:
GENERAL SESSION 4:
GENERAL SESSION 5:
GENERAL SESSION 6:
Press Conferences
Wednesday December 6 @ 7:15 a.m.
Wednesday December 6 @ 12:15 p.m
Thursday December 7 @ 7:30 am
Friday December 8 @ 7:30 am
Interviews & Brustkrebs Deutschland Round Table & SAKK Roundtable
Roundtable Brustkrebs Deutschland
Roundtable mit Experten aus der Schweiz
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Peyman Hadji, Marburg
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Peyman Hadji, Marburg
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin (Kopie)
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Stefan Buchholz, Regensburg
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. phil. Ute Berndt, Halle-Saale
Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr.med. Michael Untch, Berlin-Buch
Cancer Academy – Hirntumoren
7. Interdisziplinäres Prostatakarzinomsymposium
Grundlagen
Lokalisiertes & oligometastatisches Prostatakarzinom
Systemtherapien Prostatakarzinom
Advanced Breast Cancer 4th ESO-ESMO International Consensus Conference
Cancer Academy – Brustkrebs
ESMO 2017 Congress
Breast Cancer Highlights
Neoadjuvante Therapie bei luminalem, triple negativem oder HER2 positivem Brustkrebs
Luminaler Brustkrebs - wer braucht Chemotherapie?
CDK4-6 Inhibitoren beim metastasierten Brustkrebs
Abstract LBA10_PR ‘Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)’
Abstract 1472P_PR ‘Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients’
Gastrointestinal Carcinoma Highlights
Colorectal Cancer
Gastric Cancer
Head & Neck Cancer Highlights
PD Dr. med. Sacha Rothschild comments Head&Neck Cancer Studies
Abstract LBA45_PR ‘Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial’
1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
1. First line Cetuximab and Cisplatin with or without Paclitaxel/2. The observational ENCORE study: Cetuximab + platinum-based therapy
Lung Cancer Highlights
Prof. Martin Reck
PD Dr. AlessandraCurioni-Fontecedro
PD Dr. AlessandraCurioni-Fontecedro
Prof. Dr. med.Solange Peters
Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
Melanoma & Merkel Cell Carcinoma Highlights
Prof. Dr. med. Reinhard Dummer, Zurich
Prof. Dr. med. Olivier Michielin, Lausanne
Ovarian Cancer Highlights
Urogenital Cancer Highlights
Richard Cathomas, Chur, comments on the urogenital Carcinoma Highlights
Abstract LBA37_PR – ‘Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial’
Late breaking news
Opening Press Conference
LBA Press Conference: Lung cancer
Press Conference: Facing the challenges of life after cancer
LBA Press Conference: Breast cancer, Gynaecological cancers, Genito-urinary cancers
LBA Press Conference: Melanoma cancer
Wrap-Up press conference/Best of ESMO2017
Cancer Center Zürich Second - Zurich Immuno-Oncology Symposium
Welcome
Essentials of tumour immunology and immunotherapies
Clinical results, patient cases and future developments I
Clinical results, patient cases and future developments II
Clinical results, patient cases and future developments III
Management of toxicities
ESMO 19th World Congress on Gastrointestinal Cancer
Cancer of the Pancreas
Session II: Cancer of the Pancreas & bile Ducts
Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology
Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate
Interview mit Prof. Gerald Prager, Wien
Colon Cancer Highlights
Session XIX: Colorectal Cancer
Prof. Dr. med. Bernhard Pestalozzi, UniversitätsSpital Zürich:
Die besonderen Bedürfnisse von Kindern und Jugendlichen mit Krebs
14 The International Conference on Malignant Lymphoma (ICML)
Interviews & Introductory Press Conference
Introductory Press Conference
Lymphoma Therapy
Oncoletter Interviews in cooperation with VJHEMONC
Satellite Symposia
THE FIRST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE
CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?
ELCC 2017 Genf
Cancer Academy – Lungenkrebs: Früherkennung, Diagnose und Behandlung
SENOLOGIE update 2017
Radiologie - Moderation: F. Dammann, Zürich
Genetik - Moderation: R. Morant, Rapperswil
Qualitätssicherung in der Senologie - Moderation: C. Rageth, Zürich
Operative Therapie - Moderation: C. Tausch, Zürich
Das metastasierte Mammakarzionom - Moderation: A. Müller, Winterthur
Varia - Moderation: D. Fink, Zürich
15th St.Gallen International Breast Cancer Conference
Symposium Thoracic Oncology – Guidelines and Beyond
Screening
Inquiring the molecular tumor characteristics
Shanghai meets Zürich
Treatment options in localized NSCLC
Multimodality approaches in rare thoracic tumors
Metastatic disease
Livecasts & Kongresskalender
Livecast
Kongresskalender 2021
Kongresskalender 2022
Drugs oral & i.v., Guidelines, Interaktionen
Orale Krebstherapeutika
orale Wirkstoffe A
orale Wirkstoffe B
Orale Wirkstoffe C
Orale Wirkstoffe D
Orale Wirkstoffe E
Orale Wirkstoffe F
Orale Wirkstoffe G
Orale Wirkstoffe H
Orale Wirkstoffe I
Orale Wirkstoffe L
Orale Wirkstoffe Ν
Orale Wirkstoffe O
Orale Wirkstoffe P
Orale Wirkstoffe R
Orale Wirkstoffe S
Orale Wirkstoffe T
Orale Wirkstoffe U
Orale Wirkstoffe V
Orale Wirkstoffe Z
Alle Wirkstoffe
Melden Sie fehlende Wirkstoffe
Acronyme
ALK-Inhibitors
Wirkstoffe A
Wirkstoffe B
Wirkstoffe C
Wirkstoffe D
Wirkstoffe E
Wirkstoffe F
Wirkstoffe G
Wirkstoffe H
Wirkstoffe I
Wirkstoffe K
Wirkstoffe L
Wirkstoffe M
Wirkstoffe N
Wirkstoffe O
Wirkstoffe P
Wirkstoffe Q
Wirkstoffe R
Wirkstoffe S
Wirkstoffe T
Wirkstoffe U
Wirkstoffe V
Wirkstoffe Z
Behandlungsguidelines
The Cancer Cell Line Encyclopedia
Schweizer Krebsbulletin
Oncologic emergencies
Interaktionsprüfungen
Krebserkrankungen (Entstehung, Verlauf, Therapie & Prävention)
Wissenschaftlicher Beirat Oncoletter
Nebenwirkungen & Behandlungs- vorschläge
Symptome
Allgemeine Störungen
Fatigue
Fieber/Infektion
Ödeme
Schmerzen
Stimmungsschwankungen
Atmungsorgane
Dyspnoe
Epistaxis/Nasenbluten
Pleuraerguss
Augen
Konjunktivitis
Periorbitale Oedeme
Sehstoerungen
Blut- und Lymphsystem
Anaemie
Lymphopenie
Neutropenie
Thrombozytopenie
Gastrointestinale Störungen
Abdominalschmerz
Diarrhoe
Dyspepsie
Mukositis/Stomatitis
Nausea und Erbrechen
Obstipation
Haut
Aktinische Keratose
Alopezie
Hand-Fuss-Syndrom
Hyperkeratose
Photosensivitätsreaktion
Plattenepithelkarzinom der Haut
Praevention von Pruritus, Rash, Desquamation
Pruritus
Rash, papulopustulöse, follikuläre Exantheme
Seborrhoische Keratose
Sonnenbrand
Trockene Haut
Herz, Gefässe
Arterielle Hypertonie
Blutungen
Herzinsuffizienz
Hitzewallungen
Verminderung der linksventrikulären Auswurfsfraktion (LVEF)
Leber und Galle
Dosierungsempfehlungen oraler TKI/mTor-Inhibitoren bei Leberdysfunktion
Gamma-Glutamyl-Transferase
Muskelskelettsystem
Arthralgien
Knochenschmerzen
Muskelschwaeche
Muskelverhaertungen und Muskelkraempfe
Muskuloskelettale Beschwerden/Schmerzen in den Extremitaeten/Gliederschmerzen
Myalgie/Muskelschmerzen
Rueckenschmerzen
Nervensystem
Dysgeusie
Insomnie
Kopfschmerzen
Neuropathie/Polyneuropathie
Reversible posteriore Leukenzephalopathie
Niere und ableitende Harnwege
Harnwegsinfekt
Stoffwechsel- und Ernährungsstörungen
Amylase-/Lipasewerte
Anorexie
Cholesterol- oder Triglyzeridwerte
Gewichtszunahme
Glucosewerte
Hypokaliämie
Hypokalzämie
Hypophosphatämie
Hypothyreose
Referenzen
Nutzungsbestimmungen
Organisationen & Science Board
Science Board
Fachgesellschaften
Info für PatientINNen
Netzwerke
Startseite
Kongressberichte & Archiv
Archiv 2020
ESMO VIRTUAL 2020
Thoracic Cancer
Navigation überspringen
Presidential Symposia
1-3
Presidential Symposium I
Osimertinib adjuvant in resected EGFRm NSCLC (ADAURA): CNS disease recurrence; Lorlatinib vs crizotinib 1st-line in advanced ALK-positive NSCLC (CROWN); Nivolumab + cabozantinib vs sunitinib 1st-line for advanced RCC (CheckMate 9ER)
Presidential Symposium II
PORT to no PORT in completely resected NSCLC & mediastinal N2; ipatasertib + abiraterone vs placebo (pbo) plus abi in mCRPC; Olaparib vs physician’s choice of enzalutamide or abiraterone in mCRPC & HRR gene alteration; Abemaciclib in high risk EBC
Presidential Symposium III
Nivo+CT vs CT 1st-line GC/GEJC)/EAC): CheckMate 649; Nivo+CT vs CT alone in untreated advanced/recurrent G/GEJ: ATTRACTION-4; Pembro+CT vs CT 1st-line in advanced EC: KEYNOTE-590; Adjuvant nivo in resected EC/GEJC following neoadjuvant CRT: CheckMate 577
Breast cancer
Early stage; metastatic 1 & 2
Interviews
Themen: Tucatinib & QoL/Hirnmetastasen; TNBC & Atezolizumab/CT; Abemaciclib adjuvant bei hohem HR+, HER2- Risiko; News HR+ MammaCa; MONLEESA Studien 2,3 & 7: gepoolte Analysen; ASCENT; IMpassion031; ESMO Livetime Achievement Award Nadia Harbeck
Proffered Paper - Breast cancer, early stage
IMpassion031; GeparOcto; PALLAS: adj palbociclib + endocrine therapy vs endocrine therapy alone HR+/HER2-EBC; Randomized preoperative window of opportunity (WOO) study with abemaciclib in EBC & differential gene expression pathway analyses with palbo
Proffered Paper - Breast cancer, metastatic 1
IMpassion131: 1st-line PAC±atezo in mTNBC; IMpassion130: atezo+nab-PAC vs placebo+nab-PAC in mTNBC; ASCENT: sacituzumab govitecan vs TPC in mTNBC; SOLAR-1: alpelisib+FULV in HR+HER2–ABC; nextMONARCH: abemaciclib mono or combined with TAMOX in HR+HER2-mBC
Proffered Paper - Breast cancer, metastatic 2
HRQoL & in mABC in BROCADE 3; tucatinib & HRQoL in HER2+ MBC with and without brain metastases; QOL in MONALEESA (ML)-2, -3, and -7 with ribociclib plus ET in HR+/HER2−ABC; GEICAM/2014-12 (FLIPPER) study: FULV/palbo vs F/placebo 1st-line in HR +/HER2– ABC
Thoracic Cancer
Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies; Proffered Paper - NSCLC metastatic 1 & 2
Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies
Neoadjuvant durvalumab in resectable NSCLC (IFCT-1601 IONESCO); Neoadjuvant atezo for resectable NSCLC (PRINCEPS); Consolidation ipi & nivo vs observation in limited stage SCLC after CRT (ETOP/IFCT 4-12 STIMULI); standard- or high-dose BID TRT in LS SCLC
Proffered Paper - NSCLC metastatic 1
AMG 510(sotorasib): Clinical benefit durability & biomarkers in NSCLC; Amivantamab (JNJ-61186372)+lazertinib in EGFR NSCLC; ACTIVE: Apatinib+gefitinib vs placebo+gefitinib 1st-line for advanced EGFRm NSCLC; osimertinib+/-bevacizumab in EGFR T790M mutation
Proffered Paper - NSCLC metastatic 2
SCLC with PD-L1 ≥50%; A first analysis of the PIONeeR study; nivo + carbo, pacli & beva in 1L NSCLC; WJOG @Be study: atezo + beva for non-squamous NSCLC with high PD-L1 expression
CNS- & Skin Tumours, NETs & Sarcoma
NETs - Sarcoma - CNS tumours - Melanoma and other skin tumours
Proffered Paper - NETs
Surufatinib for pancreatic neuroendocrine tumours; safety&efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive NETs; durvalumab+tremelimumab for advanced NENs of gastroenteropancreatic or lung origin; pralsetinib(BLU-667) in RET+ MTC
Proffered Paper - Sarcoma
pembrolizumab mono in selected rare sarcoma histotypes; TRAMUNE, trabectedin & durvalumab, in advanced pretreated soft tissue sarcomas; regorafenib in metastatic relapsed Ewing sarcoma (ES); Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma
Proffered Paper - CNS tumours
TERT promoter mutation & O6-MGMT promoter methylation-mediated sensitivity to temozolomide in IDH-wt glioblastoma (GB); prognostic role of MGMT methylation value by pyrosequencing assay in GB pts; density of tumour-infiltrating CTC in newly diagnosed GB
Proffered Paper - Melanoma and other skin tumours
Sparta-DabTram in BRAF V600–mutant unresectable/metastatic melanoma (MEL); Lenvatinib+Pembro in MEL; efficacy&safety from phase II SECOMBIT; Pembro vs placebo after complete resection of HR stage III MEL; Adjuvant NIVO vs IPI in resected stage III/IV MEL
GU Tumours
non prostate 1 & 2 and prostate
Proffered Paper - GU, non prostate 1
Pembrol+CT vs CT alone 1L for advanced UC: KEYNOTE-361; 1L durvalumab +/- tremelimumab vs standard of care CT in mUC (DANUBE); sacituzumab govitecan in mUC; PROs from IMvigor130; Avelumab 1L maintenance + best supportive care vs BSC alone for advanced UC
Proffered Paper - GU, non prostate 2
Kidney ccRCC immune classification enhances the predictive value of T effector & angiogenesis signatures in response to nivo; ctDNA in 847 pts with mRCC & concordance with tissue-based testing;Results from the COSMIC-021 study; The BIONIKK trial
Proffered Paper - GU, prostate
Phase I study of AMG 160, a half-life extended, PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for mCRPC; Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic pts in STAMPEDE
Gynaecological Cancers
Proffered Papers 1 & 2
Proffered Paper 1 - Gynaecological cancers
palbociclib + letrozole in ER+ advanced/recurrent EC; Radical hysterectomy in cervical cancer with intraoperatively detected positive lymph node; niraparib in platinum-sensitive recurrent ovarian cancer; trabectedin/PLD followed by platinum at progressio
Proffered Paper 2 - Gynaecological cancers
bev-containing therapy+/-atezo in stage III/IV OC; ICON8: OS of weekly dose-dense CT in 1L epithelial ovarian, fallopian tube or primary peritoneal Ca; Tisotumab vedotin in recur/metastat cervical cancer; Nivo vs gemcit or peg liposomal doxorubicin for OC
Head & Neck & GI Cancers
Proffered Papers - Head & Neck cancer - GI, colorectal - GI, non colorectal
Proffered Paper - Head & Neck cancer
Results of the GORTEC 2015-01 “PembroRad” randomized trial; JAVELIN head & neck 100 trial; high-dose cisplatin chemo-radiation + xevinapant or placebo in HR squamous cell carcinoma of the head and neck; The IMCISION trial; the EPIC-OPC Study
Proffered Paper - GI, colorectal
HRQoL in pts with pembro vs CT 1L in MSI-H and/or dMMR mCRC (KEYNOTE-177); The CAVE (cetuximab-avelumab) mCRC study; PRODIGE 13 a FFCD phase III trial; Oxaliplatin+fluoropyrimidines adjuvant for colon cancer in elderly pts, subgroup analysis from TOSCA
Proffered Paper - GI, non colorectal
HAIC with FOLFOX) vs TACE for unresectable HCC; GEM & Nab-P vs GEM, nab-P, durvalumab & tremelimumab 1L in mPDAC; The QOLIXANE trial - Real life QoL and efficacy data in 1st line pancreatic cancer from the PARAGON) registry
Immunotherapy, Translational Research & Basic Science
Proffered Papers - Investigational immunotherapy - Developmental therapeutics - Basic Science - Translational research
Proffered Papers - Investigational immunotherapy
lenvatinib+pembro in advanced solid tumours; Sym021 (anti-PD-1 AB) alone & combined with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3); MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in advanced solid tumours; AK104 in mesothelioma
Proffered Papers - Developmental therapeutics
MK-4830 in advanced solid tumours; PRS-343, a HER2/4-1BB bispecific molecule, in HER2+ malignancies; Nivo in edPOLE MMRp advanced tumours; CC-90010, a BET inhibitor in solid tumours & (R/R) non-Hodgkin lymphoma; CC-90011 in advanced solid tumours & R/R NH
Proffered Papers - Basic Science
Cancer dissemination from metastatic intermediates of hypermethylated CRC reveals new mode of collective migration; inactivation of E-cadherin drives EMT-less metastasis; GDF-15 neutralization reverses cancer cachexia; Efficacy of ER Receptor/CDK4/6/PI3K
Proffered Papers - Translational research
Meta-analysis of tumour & T cell intrinsic mechanisms of sensitization to checkpoint inhibition; Soluble PD-L1 & circulating CD8+PD1+ & NK cells enclose a highly prognostic & predictive immune effector score in NSCLC immunotherapy & 3 more papers
SARS-CoV-2 & Cancer
Proffered Papers SARS-CoV-2 & Cancer 1 & 2
Proffered Paper - SARS-CoV-2 and cancer 1
Impact of COVID-19 on management of cancer therapy & psychological consequence for the pts; impact on oncology professionals; Systemic cancer treatment-related outcomes in patients with SARS-CoV-2; Prospective data of 1,797 hospitalised CA-pts & COVID-19
Proffered Paper - SARS-CoV-2 and cancer 2
Clinical and laboratory prognostic factors in CA-pts & SARS-CoV-2; The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01; Disparities in cancer during the COVID-19 pandemic; Defining COVID-19 outcomes in thoracic cancer pts
Supportive & Palliative Therapy, Public Policy
Proffered Papers - Supportive and palliative care & Public Policy
Proffered Paper - Supportive and palliative care
A pragmatic cluster-randomized trial of ambulatory toxicity management in patients receiving adjuvant or neo-adjuvant CT for early stage breast cancer; TRheuMa registry on rheumatic immune-related AEs; QoL with immune checkpoint inhibitors; 2 more papers
Proffered Paper - Public Policy
EU cancer burden for 2020; Access disparities to clinical trials in EU; Developing a real-world outcomes forecast model using matched oncology clinical trials; Clinical benefit of cancer drugs approved in Switzerland; HTA in England, France & Germany
ESMO VIRTUAL CONGRESS 2020
Selection of some sessions of interest
Navigation überspringen
ESMO World Congress on Gastrointestinal Cancer 2021
International Conference on Malignant Lymphoma (ICML)
EHA2021 Virtual Congress
2021 ASCO Annual Meeting
American Association for Cancer Research (AACR) Annual Meeting 2021
ELCC 2021
47th Annual Meeting of the European Society for Blood and Marrow Transplantation
Brustkrebsinfotag 2021
News der Leitlinienkommission der AGO Mamma 2021
Archiv 2020
2020 San Antonio Breast Cancer Virtual Symposium
All-Virtual 62nd ASH Annual Meeting and Exposition
52th Congress of the International Society of Paediatric Oncology (SIOP)
DGHO, OeGHO, SGMO und SGH+SSH Jahrestagung 2020 VIRTUAL
EBCC-12 European Breast Cancer Conference
ESMO VIRTUAL 2020
Presidential Symposia
Breast cancer
Thoracic Cancer
Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies
Proffered Paper - NSCLC metastatic 1
Proffered Paper - NSCLC metastatic 2
CNS- & Skin Tumours, NETs & Sarcoma
GU Tumours
Gynaecological Cancers
Head & Neck & GI Cancers
Immunotherapy, Translational Research & Basic Science
SARS-CoV-2 & Cancer
Supportive & Palliative Therapy, Public Policy
ESMO VIRTUAL CONGRESS 2020
VIRTUAL EBMT 46th Annual Meeting 2020
IASLC 21st World Conference on Lung Cancer
The 22nd ESMO World Congress on Gastrointestinal Cancer - Virtual Congress
Virtual Edition of the 25th Annual Congress of the European Hematology Association
ASCO20 Virtual Scientific Meeting
SAMO Virtual Workshop on COVID19:
Coronavirus/Brustkrebs
AGO MAMMAKARZINOM - State of the Art Meeting 2020
Ten Years of ETOP
2nd Zurich Brain Metastasis Symposium
SABCS - 42nd Annual San Antonio Breast Cancer Symposium
61st ASH Annual Meeting and Exposition
Gene Therapy and Transfer
CAR-T-Zell Therapie in der Schweiz
Archiv 2019
Archiv 2018
Archiv 2017
News
LONSURF® approved & reimbursed in 3L mGC
02-08-2021 06:00
Compendium
(d)
Compendium
(f)
First-line NIVO + CT vs CT alone for advanced gastric, gastro-oesophageal junction, & oesophageal adenocarcinoma (CheckMate 649): a new standard
07-07-2021 12:45
Weiterlesen ...
Blood test for early detection of cancer: final study results support screening use. Test can detect over 50 types of cancer, often before symptoms show
24-06-2021 23:01
Weiterlesen ...
Swissmedic Approves TEPMETKO® a Once-Daily Targeted Therapy for NSCLC with a METex14 Skipping Mutation1
23-06-2021 11:32
Weiterlesen ...
Isatuximab + carfilzomib–dexamethasone: a new standard of care for R/R MM
21-06-2021 08:58
Weiterlesen ...
Lehrvideo zur Entfernung von Bauchspeicheldrüsentumoren mittels Robotik
16-04-2021 08:42
Weiterlesen ...
New Standard of Care: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
03-04-2021 08:40
Weiterlesen ...
Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer
26-03-2021 09:58
Go to the
ELCC/ESMO 2021 PRESS RELEASE
SECOND DRUG TARGETING KRAS G12C SHOWS BENEFIT IN MUTATED NON-SMALL-CELL LUNG CANCER
25-03-2021 17:15
Go to the
ELCC/ESMO 2021 PRESS RELEASE
Newsletter
Firstname
Name
E-Mail*
Arzt*
Ja
Nein
Neu laden
Bitte geben Sie den Schriftzug ein!
